carbostyril has been researched along with HIV Coinfection in 245 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (1.63) | 18.2507 |
| 2000's | 25 (10.20) | 29.6817 |
| 2010's | 183 (74.69) | 24.3611 |
| 2020's | 33 (13.47) | 2.80 |
| Authors | Studies |
|---|---|
| Calcagno, A; Calza, S; Castelli, F; Cattelan, AM; Celesia, BM; Chiesa, A; De Socio, G; Ferrara, M; Focà, E; Guaraldi, G; Madeddu, G; Milic, J; Nozza, S; Orofino, G; Piconi, S; Renzetti, S; Siano, M | 1 |
| Gao, LY; Hu, Y; Huang, XJ; Ma, P; Wu, H; Wu, Y; Xia, H; Yan, ZF | 1 |
| Chang, SF; Chang, SY; Chuang, YC; Hsiao, CY; Hsieh, TW; Hsu, JY; Huang, YS; Hung, CC; Liu, WC; Su, YC; Sun, HY | 1 |
| Aydin, OA; Bilge, B; Bolukcu, S; Dokmetas, I; Gumuser, F; Gunduz, A; Karaosmanoglu, HK; Mete, B; Tabak, F; Yildiz, DS | 1 |
| Barry, S; Chopra, A; Ibrahim, A; Pokhrel, K; Smith, T | 1 |
| Dee, N; Dewar, R; George, J; Grossman, Z; Hill, S; Huik, K; Khan, M; Kuriakose, S; Lange, CM; Maldarelli, F; Pau, A; Rehm, CA; Rehman, T; Stoll, P | 1 |
| Brummel, SS; Chadwick, EG; Huo, Y; Jacobson, DL; Jao, J; Kacanek, D; Kahlert, CR; Patel, K; Powis, KM; Seage, GR; Shiau, S; Sultan-Beyer, L; Williams, PL; Yee, LM; Zash, R | 1 |
| Cao, T; He, Y; Jia, X; Ju, B; Liu, J; Liu, X; Peng, Q; Rao, M; Song, Y; Sun, L; Wang, H; Wang, S; Xu, L; Zhang, H; Zhang, L; Zhang, Q; Zhao, F; Zhou, J; Zhou, Y | 1 |
| Brehm, TT; Degen, O; Franz, M; Hertling, S; Hüfner, A; Kreuels, B; Schmiedel, S; Schulze Zur Wiesch, J | 1 |
| Chen, SQ; Li, Q; Yang, LL; Zhou, LB | 1 |
| Burgi, A; Letendre, SL; Little, SJ; Ma, Q; Morse, GD; Ocque, AJ; Sanders, C | 1 |
| Castagna, A; Gianotti, N | 1 |
| Das, M; Haubrich, R; Maggiolo, F; Mateo-Garcia, MG; McNicholl, I; Molina, JM; Ong, E; Piontkowsky, D; Pulido, F; Raffi, F; Rizzardini, G; Shao, Y | 1 |
| Bezenchek, A; Borghetti, A; Callegaro, A; Colafigli, M; Costantini, A; De Luca, A; Di Carlo, D; Farinacci, D; Ferrara, SM; Gagliardini, R; Gianotti, N; Giombini, E; Gismondo, MR; Lombardi, F; Maggiolo, F; Modica, S; Redi, D; Rossetti, B; Rusconi, S; Sterrantino, G; Zazzi, M | 1 |
| Albanesi, E; Appendino, A; Boccuto, A; Dragoni, F; Giannini, A; Saladini, F; Vicenti, I; Zazzi, M | 1 |
| Hollenbeck, BL; Kishore, S; Lee, MSL; Padival, S | 1 |
| Biasiotto, G; Bonito, A; Calza, S; Castelli, F; Quiros-Roldan, E; Vezzoli, M; Zanella, I | 1 |
| Ajana, F; Bani-Sadr, F; Bouvet, E; Cotte, L; Galempoix, JM; Gantner, P; Hessamfar, M; Hustache-Mathieu, L; Lebrette, MG; Muret, P; Pellissier, G; Piroth, L; Rey, D; Rouveix, E; Simon, A; Souala, MF; Truchetet, F; Valin, N | 1 |
| Butler, AM; O'Halloran, JA; Olsen, MA; Powderly, WG; Sahrmann, J | 1 |
| Bukkems, V; Burger, D; Colbers, A; Garcia, C; Konopnicki, D; Lambert, JS; Necsoi, C; Rockstroh, J; Schwarze-Zander, C; Tenorio, CH | 1 |
| Chitongo, R; Cloete, R; Jacobs, GB; Mikasi, SG; Obasa, AE | 1 |
| Dicker, I; Higley, H; Jenkins, S; Krystal, M; Lin, Z; Mathur, A; Meanwell, NA; Naidu, BN; Panja, C; Parker, D; Patel, M; Protack, T; Rampulla, R; Terry, B; Walker, MA | 1 |
| Chen, H; Chowdhury, P; Gong, Y; Gorantla, S; Kumar, S; Nagesh, PKB; Sinha, N; Yallapu, MM; Zhi, K | 1 |
| Castagna, A; Fornabaio, C; Galli, L; Malena, M; Menozzi, M; Poli, A; Santoro, MM; White, KL; Zazzi, M | 1 |
| Amador, C; de Zárraga, MA; Díez Martínez, M; Górgolas, M; Jarrín, I; Moreno, C; Navarro, M; Pérez-Elías, MJ; Pérez-Martínez, L; Ruiz-Algueró, M; Suárez-García, I; Viciana, P | 1 |
| Cong, ME; Dinh, C; García-Lerma, JG; Haaland, R; Heneine, W; Holder, A; Johnson, R; Kelley, CF; Kelley, K; Khalil, G; Massud, I; Mills, P; Pan, Y; Ruone, S; Sanchez, T; Zlotorzynska, M | 1 |
| Chang, SF; Chang, SY; Chen, GJ; Cheng, CY; Chuang, YC; Hsieh, MH; Huang, SH; Hung, CC; Lee, CH; Lee, YC; Lee, YL; Su, LS; Sun, HY; Tang, HJ; Tsai, HC | 1 |
| Cloete, R; Ikomey, GM; Isaacs, D; Jacobs, GB; Mikasi, SG; Obasa, AE; Shityakov, S | 1 |
| Festa, L; Grinspan, JB; Jordan-Sciutto, KL; Monnerie, H; Putatunda, R; Romer, M; Roth, LM; Zidane, B | 1 |
| Amano, K; Hachiya, A; Ichiki, A; Kinai, E; Yotsumoto, M | 1 |
| Adams, JL; Baxter, J; Choi, YC; George, J; Pontiggia, L; West, M | 1 |
| DeMarais, P; Max, B | 1 |
| Cheng, CY; Cheng, SH; Ho, MW; Huang, SH; Huang, YS; Hung, CC; Lee, CH; Lee, YT; Lin, SP; Liou, BH; Liu, CE; Lu, PL; Sun, HY; Tang, HJ; Tsai, HC; Yang, CJ | 1 |
| Ma, R; Tong, ZW; Xu, B; Zhang, Q; Zhang, YS; Zhao, CS; Zhao, RG | 1 |
| Castagna, A; Esser, S; Haubrich, R; Llibre, JM; Margot, N; McNicholl, IR; Molina, JM; Perez-Valero, I; Piontkowsky, D; Pulido, F; Shao, Y; Temme, L | 1 |
| Adimora, AA; Dastgheyb, R; Fischl, MA; Fitzgerald, KC; Gustafson, DR; Kamkwalala, AR; Konkle-Parker, D; Lahiri, CD; Maki, PM; Milam, J; O'Halloran, JA; Ofotokun, I; Rubin, LH; Sharma, A; Sheth, AN; Spence, AB; Wang, K; Weber, KM; Williams, DW; Xu, Y | 1 |
| Bendtsen, F; Benfield, T; Gelpi, M; Kirkegaard-Klitbo, DM; Nielsen, SD; Thomsen, MT | 1 |
| Chimukangara, B; Gordon, M; Mbhele, N | 1 |
| Blanch, J; Blanco, JL; de Lazzari, E; Gatell, JM; Gonzalez-Cordon, A; Laguno, M; Lonca, M; Mallolas, J; Marcos, MA; Martinez, E; Martinez-Rebollar, M; Padilla, M; Peñafiel, J; Rodriguez, A; Rojas, J; Tricas, A | 1 |
| Castagna, A; Chiappetta, S; Galli, L; Lazzarin, A; Nozza, S; Poli, A; Ripa, M; Rovelli, C; Spagnuolo, V; Tambussi, G | 2 |
| Al Tabaa, O; Audren, V; Blum, L; Hayton, E; Pertuiset, E | 1 |
| Aitken, C; Bradley-Stewart, A; Gunson, R; MacLean, A; Urcia, C | 1 |
| Buclin, T; Decosterd, L; Francini, K; Livio, F; Marzolini, C; Tissot, F; Winterfeld, U | 1 |
| Angione, SA; Cherian, SM; Özdener, AE | 1 |
| Avettand-Fenoel, V; Bellecave, P; Bonnet, F; Caldato, S; Hessamfar, M; Morlat, P; Ngo Bell, EC; Saunier, A; Tumiotto, C; Vandenhende, MA | 1 |
| Hughes, CA; Phillips, EJ; Seet, J; Tseng, A; Wu, J | 1 |
| Balboa-Barreiro, V; Castro-Iglesias, Á; Cid-Silva, P; Fernández-Bargiela, N; Llibre, JM; Margusino-Framiñán, L; Martín-Herranz, I; Pernas-Souto, B; Poveda, E | 1 |
| Bandera, A; Bonfanti, P; Calza, L; Carenzi, L; Celesia, BM; Cordier, L; De Socio, GV; Di Biagio, A; Falasca, K; Gori, A; Madeddu, G; Maggi, P; Martinelli, C; Orofino, G; Pellicanò, GF; Quirino, T; Ricci, E; Rusconi, S; Squillace, N; Vichi, F | 1 |
| Andreatta, K; Antinori, A; Berenguer, J; Bloch, M; Cote, P; Flamm, J; Garner, W; McColl, DJ; Nguyen-Cleary, T; Piontkowsky, D; Pozniak, A; Szwarcberg, J; Ward, D | 1 |
| Baecke, C; Decoutere, L; Gyssens, IC; Messiaen, P; van der Hilst, JCH | 1 |
| Clark, MR; Deng, Y; Mohideen, M; Panse, G; Quijano, E; Saltzman, WM; Song, E; Zhang, W | 1 |
| Alessandri-Gradt, E; Bertine, M; Charpentier, C; Collin, G; Descamps, D; Leoz, M; Plantier, JC; Tourneroche, A; Unal, G | 1 |
| Cao, H; Chang, S; Hodder, SL; Kulkarni, R; Miller, MD; White, KL | 1 |
| Calvez, V; Charpentier, C; Collin, G; Delelis, O; Descamps, D; Malet, I; Marcelin, AG; Subra, F | 1 |
| Baldelli, S; Cattaneo, D; Clementi, E; Galli, M; Gervasoni, C; Giacomelli, A; Mazzali, C; Meraviglia, P; Milazzo, L; Minisci, D; Resnati, C; Rizzardini, G | 1 |
| Arnaiz, JA; Cruceta, A; García, F; Gatell, JM; González, E; González-Cordón, A; Inciarte, A; Laguno, M; Leal, L; León, A; Lucero, C; Mallolas, J; Martínez-Rebollar, M; Rojas, J; Torres, B | 1 |
| Ganase, B; Harrigan, PR; Harris, M; Hull, MW; Montaner, JSG; Watson, B | 1 |
| DeJesus, E; Haas, B; Liu, YP; Makadzange, T; Margot, N; McCallister, S; Mills, A; Ramgopal, MN; Segal-Maurer, S | 1 |
| Akagi, L; Barrios, R; Guillemi, S; Lepik, KJ; Lima, VD; Montaner, JSG; Toy, J; Ulloa, AC; Wang, L; Yip, B | 1 |
| Avihingsanon, A; Cao, H; Cheng, A; Hagins, D; Hodder, S; Jiang, S; Kido, A; Kityo, C; Kulkarni, R; Squires, K | 1 |
| Domingo, JC; Domingo, P; Gallego-Escuredo, JM; Gasa, L; Giralt, M; Maroto, AF; Mateo, GM; Morón-Ros, S; Moure, R; Quesada-López, T; Villarroya, F; Villarroya, J | 1 |
| Cogill, D; Hamers, RL; Lane, HC; Larder, BA; Montaner, JSG; Perez-Elias, MJ; Pozniak, A; Rehm, CA; Reiss, P; Revell, AD; Tempelman, H; van Sighem, AI; Wang, D; Wood, R | 1 |
| Burger, DM; Colbers, A; Greupink, R; Schalkwijk, SJ; Ter Heine, R; van der Galiën, R; van Herwaarden, AE | 1 |
| Adorni, F; Borghi, V; Bruzzone, B; Di Biagio, A; Francisci, D; Mancon, A; Maserati, R; Meraviglia, P; Micheli, V; Monno, L; Paolucci, S; Pecorari, M; Punzi, G; Rusconi, S; Tau, P; Zazzi, M | 1 |
| Anstett, K; Brenner, BG; Ibanescu, RI; Mésplède, T; Oliveira, M; Robbins, MA; Routy, JP | 1 |
| Acosta, EP; Badell, ML; Barr, E; Best, BM; Burchett, S; Capparelli, EV; Chakhtoura, N; Mirochnick, M; Momper, JD; Park, K; Purswani, M; Shapiro, DE; Smith, E; Stek, A; Wang, J | 1 |
| Álvarez, H; Díaz-Cambre, H; García-González, J; Llibre, JM; Mariño, A; Valcarce, N | 1 |
| Álvarez, H; Llibre, JM; Yzusqui, M | 1 |
| Chauhan, M; Chokkar, N; Kalra, S; Kumar, R | 1 |
| Cabot, JF; Denault, JS; Langlois, H; Marcotte, S; Sheehan, NL | 1 |
| Bagella, P; Baldin, G; Capetti, A; Ciccullo, A; Cossu, MV; De Luca, A; Di Giambenedetto, S; Giacomelli, A; Lagi, F; Latini, A; Madeddu, G; Rusconi, S; Sterrantino, G | 1 |
| Bruzzone, B; D'Autilia, R; De Luca, A; Di Biagio, A; Francisci, D; Lagi, F; Lombardi, F; Maffeo, M; Magnani, G; Modica, S; Paolucci, S; Pecorari, M; Penco, G; Rossetti, B; Sacchini, D; Vicenti, I; Zazzi, M | 1 |
| Andreoni, M; Cerva, C; Maffongelli, G; Malagnino, V; Sarmati, L; Teti, E | 1 |
| Cortina-Borja, M; Peters, H; Rasi, V; Sconza, R; Thorne, C | 1 |
| Allavena, C; Bani-Sadr, F; Bregigeon, S; Cabié, A; Cuzin, L; Ferry, T; Katlama, C; Lourenco, J; Pugliese, P; Rey, D; Reynes, J | 1 |
| Cottrell, ML; Garcia, B; Imaz, A; Kashuba, ADM; Morenilla, S; Niubó, J; Perez, E; Podzamczer, D; Tiraboschi, JM | 1 |
| Capetti, AF; Cossu, MV; Giacomet, V; Rizzardini, G; Zuccotti, G | 1 |
| Fujiwara, T; Kawauchi-Miki, S; Miki, S; Seki, T; Yoshinaga, T | 1 |
| Brown, SD; Cluck, DB; Duffourc, MM; Harirforoosh, S; Moorman, JP; Murrell, DE; Wang, KS | 1 |
| Abdulghani, N; Ambrosioni, J; Casabona, J; Curran, A; Domingo, P; Force, L; Homar, F; Llibre, JM; Miró, JM; Montoliu, A; Peraire, J; Riera, M; Tiraboschi, J | 1 |
| Antinori, A; Castagna, A; Costantini, A; Cozzi-Lepri, A; d'Arminio Monforte, A; Di Biagio, A; Gianotti, N; Lo Caputo, S; Marchetti, G; Mazzarello, G; Mazzotta, V; Rusconi, S | 1 |
| Bugnon, S; Godinho, R; Gracin, T; Tataw, J | 1 |
| Alfaro, J; Bogdanov, AA; Bolotin, E; Castillo, G; Gottikh, MB; Gupta, S; Leporati, A | 1 |
| Abo, YN; Foster, C; Lyall, H; Mackie, N; Refsum, E; Tudor-Williams, G | 1 |
| Baldelli, S; Cattaneo, D; Gervasoni, C; Ridolfo, A | 1 |
| Beeker, N; Chouchana, L; Treluyer, JM | 1 |
| Cassetti, I; Castillo, S; Cecchini, DM; Copertari, G; Lacal, V; Rodriguez, CG | 1 |
| Ambrosioni, J; de Lazzari, E; García, F; Marcos, MÁ; Miró, JM; Mosquera, MM; Nicolás, D; Rico, JÁF | 1 |
| Kaplun, O; Psevdos, G | 1 |
| Alteri, C; Andreoni, M; Antinori, A; Bezenchek, A; Borghi, V; Cascio, A; De Luca, A; Di Carlo, D; Incardona, F; Perno, CF; Santoro, MM; Scutari, R; Vicenti, I; Zazzi, M; Zuccaro, V | 1 |
| Conway-Washington, C; Dinh, C; Fountain, J; Haaland, RE; Hall, L; Holder, A; Kelley, CF; Livermont, T; Lupo, LD; Martin, A | 1 |
| Abram, ME; Callebaut, C; Margot, NA; Ram, RR; White, KL | 1 |
| Karmon, SL; Markowitz, M | 1 |
| Abram, ME; Andreatta, KN; Barnes, TL; Chen, X; Goodman, DD; Hluhanich, RM; Margot, NA; McColl, DJ; Miller, MD; Niedziela-Majka, A; Novikov, N; Svarovskaia, ES; White, KL; Ye, L | 1 |
| Bruce, RD; Custodio, JM; Friedland, GH; Kearney, BP; Ramanathan, S; Rhee, MS; Wei, LX; Winkle, P | 1 |
| Aouri, M; Buclin, T; Calmy, A; Cavassini, M; Decosterd, LA; Hirschel, B; Rauch, A; Telenti, A | 1 |
| Fransen, S; Frantzell, A; Huang, W; Petropoulos, CJ | 1 |
| Burioni, R; Canducci, F; Castagna, A; Ceresola, ER; Clementi, M; Gianotti, N; Lazzarin, A; Saita, D; Underwood, M | 1 |
| Chuck, SL; Conway, B; Cooper, D; Elion, R; Liu, YP; Maggiolo, F; Margot, N; Molina, JM; Ramón Arribas López, J; Rhee, M; Szwarcberg, J; Wilkins, E | 1 |
| Aldir, I; Horta, A; Serrado, M | 1 |
| Perry, CM | 1 |
| Ait-Khaled, M; Castagna, A; Chas, J; Doroana, M; Durant, J; Grossberg, R; Huang, J; Maggiolo, F; Mills, A; Min, S; Molina, JM; Moreno, S; Nichols, G; Penco, G; Song, I; Vavro, C; Wright, D; Yeo, JM | 1 |
| Doyon, G; Huber, K; McMahon, D; Mellors, JW; Sluis-Cremer, N; Sobolewski, MD | 1 |
| Gupta, S; Jayaswal, A; Mishra, H; Shah, K; Sharma, PK | 1 |
| Hsiao, CB; Ma, Q; Sawyer, JR | 1 |
| Deeks, ED | 1 |
| Abraham, T; Saad, N; Wu, G | 1 |
| Reviriego, C | 1 |
| Alcaro, S; Artese, A; Calvez, V; Ceccherini-Silberstein, F; Costa, G; Delelis, O; Gimferrer Arriaga, L; Katlama, C; Malet, I; Marcelin, AG; Parrotta, L; Tmeizeh, A; Valantin, MA | 1 |
| Ayala-Sims, VA; Fulco, PP | 1 |
| Buskin, SE; Collier, AC; Frenkel, LM; Holte, S; Maenza, J; McKernan, J; Milne, R; Mullins, JI; Mykhalchenko, K; Stekler, JD; Stevens, CE; Tapia, KA | 1 |
| Debyser, Z; Schrijvers, R | 2 |
| Arribas, JR; Di Perri, G; Ebrahimi, R; Gathe, J; Nguyen, T; Pialoux, G; Piontkowsky, D; Reynes, J; Tebas, P; White, K | 1 |
| Antela, A; Domingo, P; Garner, W; Girard, PM; Guyer, B; Henry, K; Markowitz, M; Mills, A; Nguyen, T; Piontkowsky, D; Pozniak, A; Stellbrink, HJ; White, K | 1 |
| Bruzzone, B; Di Biagio, A; Gustinetti, G; Prinapori, R; Sticchi, L; Taramasso, L; Viscoli, C | 1 |
| Miller, MD; Raffi, F; White, KL | 1 |
| Arendt, V; Lambert, C; Seguin-Devaux, C; Zheng, Y | 1 |
| Cheng, AK; Kulkarni, R; McColl, DJ; Miller, MD; Rhee, MS; Szwarcberg, J; White, KL | 1 |
| Chan, CN; Connick, E; Folkvord, JM; Lee, CS; Levy, DN; Luo, Y; Mahajan, S; Muesing, MA; Pham, M; Trinité, B | 1 |
| Fujiwara, T; Garvey, EP; Johns, BA; Kawasuji, T; Kawauchi-Miki, S; Kobayashi, M; Miki, S; Sato, A; Seki, T; Suyama-Kagitani, A; Taishi, T; Underwood, MR; Wakasa-Morimoto, C; Yoshinaga, T | 1 |
| Abram, ME; Andrade-Villanueva, JF; Beraud, C; Cheng, AK; Fisher, M; Graham, H; Liu, Y; Post, FA; Rhee, MS; Szwarcberg, J; Winston, J | 1 |
| Fisher, M; Raffe, S | 1 |
| Amiel, C; Barin, F; Bettinger, D; Calvez, V; Charpentier, C; Delaugerre, C; Descamps, D; Flandre, P; Fourati, S; Jeulin, H; Le Guillou-Guillemette, H; Maillard, A; Marcelin, AG; Mirand, A; Montès, B; Morand-Joubert, L; Nicot, F; Reigadas, S; Rodallec, A; Signori-Schmuck, A; Trabaud, MA; Vallet, S | 1 |
| Harirforoosh, S; Moorman, JP; Murrell, DE | 1 |
| Clotet, B; Llibre, JM | 1 |
| Baeten, JM; Wyatt, C | 1 |
| Andrade-Villanueva, J; Callebaut, C; Cao, H; Cheng, AK; Crofoot, G; Custodio, JM; DeJesus, E; Fordyce, MW; Koenig, E; Martin, H; McCallister, S; Molina, JM; Oka, S; Plummer, A; Podzamczer, D; Post, F; Pozniak, A; Saag, M; Sax, PE; Thompson, M; Trottier, B; Wohl, D; Yin, MT; Zhong, L | 1 |
| Fulco, PP; Gomes, DC; Good, BL | 1 |
| Stone, L | 1 |
| Blume, M; Brodt, HR; de Leuw, P; Kann, G; Schüttfort, G; Stephan, C; Wolf, T | 1 |
| Chung, S; Cosconati, S; Costi, R; Cuzzucoli Crucitti, G; Di Leva, FS; Di Santo, R; Le Grice, SF; Madia, VN; Marchand, C; Marinelli, L; Masoaka, T; Messore, A; Métifiot, M; Novellino, E; Pescatori, L; Pommier, Y; Pupo, G; Saccoliti, F; Scipione, L; Tortorella, S | 1 |
| Blanco, JL; Milinkovic, A; Moyle, G; Whitlock, G | 1 |
| Bender, R; Berenguer, J; Garner, W; Mills, A; Nguyen, T; Pozniak, A; Speck, RM | 1 |
| Abadi, J; Dehority, W; Viani, RM; Wiznia, A | 1 |
| Anstett, K; Liang, J; Mesplède, T; Oliveira, M; Wainberg, MA | 1 |
| Gauthier, TP; Schafer, JJ; Sherman, EM; Unger, NR; Worley, MV | 1 |
| Custodio, JM; Gordi, T; Ling, KH; Ramanathan, S; Zhong, L | 1 |
| Holguín, Á; Llácer Delicado, T; Torrecilla, E | 1 |
| Abram, ME; Arribas, JR; Avihingsanon, A; Benson, P; Bloch, M; Cheng, A; Chetchotisakd, P; Crofoot, G; Custodio, JM; Fordyce, MW; Gathe, J; Gupta, SK; Lichtenstein, K; McCallister, S; Post, FA; Pozniak, A; Ramgopal, M; SenGupta, D; Wei, X | 1 |
| Bonora, S; Calcagno, A; Di Perri, G; Trentalange, A | 1 |
| Trustman, N; Wong, E; Yalong, A | 1 |
| Arribas, JR; Brinson, C; Brunetta, J; Callebaut, C; Cheng, A; Cheret, A; Clarke, A; Clumeck, N; Das, M; Fordyce, M; Mussini, C; Oka, S; Rashbaum, B; Sax, PE; Stephens, J; Tashima, K; Tebas, P; Wohl, D; Zhong, L | 1 |
| Callebaut, C; Fordyce, M; Kitrinos, KM; Margot, NA; McCallister, S; Miller, MD | 1 |
| Burger, D; Colbers, A; Greupink, R; Konopnicki, D; Russel, FG; Schalkwijk, S | 1 |
| Bertucci, R; Bonora, S; Calcagno, A; D'Avolio, A; Di Perri, G; Mornese Pinna, S; Motta, I; Simiele, M | 1 |
| Klein, D; Pinsky, BA; Shafer, RW; Smith, DS; Varghese, V | 1 |
| Godbole, S; Paranjape, R; Pawar, J; Shete, A; Suryawanshi, P; Thakar, M | 1 |
| Aouri, M; Barceló, C; Buclin, T; Cavassini, M; Csajka, C; Decosterd, LA; Gaspar, F; Guidi, M; Panchaud, A; Rotger, M | 1 |
| Benson, P; Brinson, C; Brunetta, J; Cheng, A; Crofoot, G; Das, M; Fordyce, M; Gallant, J; Garner, W; McCallister, S; Mills, A; Oka, S | 1 |
| Deeks, ED; Greig, SL | 1 |
| Jones, R; Levy, JB; Milburn, J | 1 |
| Behrens, G; Borg, P; Bouee, S; M Llibre, J; Moyle, G; Piontkowsky, D; Raffi, F; Reilly, G; Rogatto, F | 1 |
| Amara, A; Back, D; Boffito, M; Challenger, E; Egan, D; Elliot, E; Else, L; Fawcett, S; Khoo, S; Penchala, SD | 1 |
| Fletcher, CV; Podany, AT; Scarsi, KK | 1 |
| Cattaneo, D; Gervasoni, C; Invernizzi, A; Micheli, V; Resnati, C; Riva, A | 1 |
| Han, YS; Mesplède, T; Wainberg, MA | 1 |
| Destache, CJ; Mandal, S; Prathipati, PK | 1 |
| Deng, Z; Huang, X; Li, M; Luo, J; Qin, Z; Wang, B; Wang, H; You, J | 1 |
| Avihingsanon, A; Cao, H; Cheng, A; Hagins, D; Hodder, S; Jiang, S; Johnson, M; Kityo, C; Koenig, E; Squires, K; Szwarcberg, J; Voronin, E; White, K | 1 |
| Di Cristanziano, V; Esser, S; Heger, E; Jensen, B; Kaiser, R; Knops, E; Lübke, N; Pironti, A; Remmel, K; Theis, AA; Walter, H | 1 |
| Batra, J; Chakraborty, R; Gaur, AH; Kizito, H; Kosalaraksa, P; Luesomboon, W; Myers, M; Porter, D; Prasitsueubsai, W; Quirk, E; Rakhmanina, N; Rassool, M; Rhee, MS; SenGupta, D; Shao, Y; Ting, L | 1 |
| Childs-Kean, LM; Kisgen, JJ; Sherman, EM; Unger, NR; Worley, MV | 1 |
| Boffito, M; Chirwa, M; Elliot, E | 1 |
| Benmarzouk-Hidalgo, OJ; Espinosa, N; Fernandez-Magdaleno, T; Gutierrez-Valencia, A; Llaves, S; Lopez-Cortes, LF; Viciana, P | 1 |
| Barin, F; Bernard, L; Capitao, M; Chaix, ML; Delaugerre, C; Maakaroun-Vermesse, Z; Néré, ML; Salmona, M; Splittgerber, M; Stefic, K | 1 |
| Imaz, A; Podzamczer, D | 1 |
| Destache, CJ; Fan, W; Kang, G; Li, Q; Mandal, S; Prathipati, PK; Yuan, Z; Zhou, Y | 1 |
| Ambrosioni, J; Miró, JM; Mosquera, MM | 1 |
| Blondel, L; Charpentier, C; Descamps, D; Joly, V; Landman, R; Lê, M; Matheron, S; Perrier, M; Peytavin, G; Pinto, A; Visseaux, B; Yazdanpanah, Y | 1 |
| Kumar, S; Lukka, PB; Meibohm, B; Midde, NM; Sinha, N | 1 |
| Arribas, JR; Callebaut, C; Cheng, A; Clarke, AE; Das, M; DeJesus, E; Guo, S; Haas, B; McCallister, S; McDonald, C; Plummer, A; Sax, PE; Thompson, M; Wang, H; Wohl, DA | 1 |
| Tedaldi, EM | 1 |
| Balzarini, J; Cecchetti, V; Daelemans, D; Fravolini, A; Manfroni, G; Massari, S; Pannecouque, C; Sabatini, S; Stevens, M; Tabarrini, O | 1 |
| Bénard, A; Brun-Vézinet, F; Campa, P; Chêne, G; Collin, G; Damond, F; Descamps, D; Matheron, S; Peytavin, G; Roquebert, B | 1 |
| Rondelez, E; Stuyver, LJ; Van Baelen, K; Van Eygen, V | 1 |
| Grant, P; Zolopa, A | 1 |
| Klibanov, OM | 1 |
| Neamati, N; Odde, S; Ramkumar, K; Serrao, E | 1 |
| Amellal, B; Calvez, V; Cissé, M; Delelis, O; Derache, A; Katlama, C; Koita, V; Maïga, AI; Malet, I; Marcelin, AG; Morand-Joubert, L; Mouscadet, JF; Murphy, R; Soulie, C; Tchertanov, L | 1 |
| Alsina, M; Bennàssar, A; Guilabert, A; Mascaró, JM; Pintor, L | 1 |
| Christ, F; Debyser, Z; McNeely, M; Thys, W | 1 |
| Bellamy, R; Payne, B | 1 |
| Ariën, K; Clynhens, M; Rondelez, E; Stuyver, LJ; Van Baelen, K; Van den Zegel, P; Van Eygen, V; Winters, B | 1 |
| de Mendoza, C; Garrido, C; Soriano, V | 1 |
| Abreu, P; Barbosa, JE; Batalha, PN; Bou-Habib, DC; Castro, HC; Cirne-Santos, CC; Cunha, AC; de Souza, MC; Ferreira, VF; Garrido, V; Giongo, V; Nogueira, CM; Paixão, IC; Rodrigues, CR; Santos, Fda C; Silva, Dde O; Simonetti, BR; Souza, TM; Temerozo, JR | 1 |
| Fätkenheuer, G; Kümmerle, T; Lehmann, C; Meuer, K | 1 |
| Schafer, JJ; Squires, KE | 1 |
| Cooper, DA; Koelsch, KK | 1 |
| Berger, DS; Cheng, AK; Chuck, SL; Enejosa, JV; Kearney, BP; Lampiris, H; Zhong, L; Zolopa, AR | 1 |
| Fish, MQ; Hewer, R; Papathanasopoulos, MA; Stevens, WS; Venter, WD; Wallis, CL | 1 |
| Anies, G; Breilh, D; da Silva, D; Dupon, M; Fleury, H; Masquelier, B; Morlat, P; Neau, D; Reigadas, S; Van Baelen, K; Van Wesenbeeck, L; Wittkop, L | 1 |
| German, P; Hui, J; Kearney, BP; Warren, D; West, S | 1 |
| Bottega, L; Cecchetti, V; Daelemans, D; Gatto, B; Manfroni, G; Massari, S; Meschini, F; Palumbo, M; Pannecouque, C; Tabarrini, O | 1 |
| Aung, GL; Kawamoto, LS; O'Brien, JG; Tien, PG | 1 |
| German, P; Kearney, BP; Mathias, AA; Ramanathan, S | 1 |
| Chuck, SL; Cohen, C; DeJesus, E; Elion, R; Kearney, BP; Liu, HC; Ramanathan, S; Rashbaum, B; Ruane, P; Shamblaw, D; Warren, DR; Yale, K | 1 |
| Chen, FE; Gu, SX; He, QQ; Liu, J; Wu, HQ; Yang, LM; Zhang, X; Zheng, YT | 1 |
| Chimirri, A; De Luca, L; Debyzer, Z; Faliti, CE; Ferro, S; Gitto, R; Grazia, SD | 1 |
| Debyser, Z; Desimmie, BA; Schrijvers, R | 1 |
| Andrade-Villanueva, J; Cheng, AK; Chuck, SL; Clotet, B; Clumeck, N; Lamarca, A; Liu, YP; Margot, N; Molina, JM; Zhong, L | 1 |
| Hughes, SH; Johnson, BC; Métifiot, M; Pommier, Y | 1 |
| Lampiris, HW | 1 |
| Andreatta, KN; Hluhanich, RM; Jones, GS; Margot, NA; McColl, DJ; Miller, MD; Tsiang, M; White, KL | 1 |
| Vega, V; Wills, T | 1 |
| Caballero, E; de Mendoza, C; Garcia, F; Garrido, C; Gutierrez, F; Pattery, T; Soriano, V; Van Houtte, M; Villacian, J; Zahonero, N | 1 |
| Delaugerre, C; Nguyen, HL; Ruxrungtham, K | 1 |
| Marchand, C | 1 |
| Cheng, AK; DeJesus, E; Gathe, J; Henry, K; Kearney, BP; Molina, JM; Ramanathan, S; Rockstroh, JK; Szwarcberg, J; Wei, X; White, K; Yale, K | 1 |
| Cheng, AK; Cohen, C; DeJesus, E; Gallant, JE; Kearney, BP; Liu, HC; Mills, A; Quirk, E; Sax, PE; Szwarcberg, J; White, K; Wohl, D; Yale, K; Zhong, L; Zolopa, A | 1 |
| Bookstaver, PB; Rokas, KE; Shamroe, CL; Weissman, SB | 1 |
| Lennox, JL | 1 |
| Adams, JL; Greener, BN; Kashuba, AD | 1 |
| Blanco, JL; Martinez-Picado, J | 1 |
| Carr, A; Lee, FJ | 1 |
| Pommer, P | 1 |
| Klibanov, OM; Olin, JL; Spooner, LM | 1 |
| Hussar, DA; Martinez, LN | 1 |
| Breeze, S | 1 |
| Morrow, T | 1 |
| Temesgen, Z | 1 |
| Raffi, F; Wainberg, MA | 1 |
| Bourgeois, A; Caldwell, D; Newsom, D; Womack, S | 1 |
| Abram, M; Cheng, AK; DeJesus, E; Fordyce, MW; Gathe, J; Henry, K; Molina, JM; Plummer, A; Ramanathan, S; Rockstroh, JK; Szwarcberg, J; Wei, X | 1 |
| Cheng, AK; Cohen, C; DeJesus, E; Gallant, JE; Liu, HC; Mills, A; Plummer, A; Rhee, MS; Sax, PE; Szwarcberg, J; White, KL; Wohl, D; Zolopa, A | 1 |
| Aïdara-Kane, A; Gassama-Sow, A; Guèye, M; Guèye-N'diaye, A; M'boup, S; Perret, JL; Sow, PS | 1 |
| Antoniades, C; Knisely, A; Macdonald, C; Norris, S; Taylor, C | 1 |
| Berger, D; Cheng, AK; Cohen, C; DeJesus, E; Elion, R; Farthing, C; Hawkins, T; Kearney, BP; Markowitz, M; McColl, D; Ruane, P; Zhong, L | 1 |
| Aquaro, S; Balzarini, J; Cecchetti, V; De Clercq, E; Fravolini, A; Pannecouque, C; Perno, CF; Pollicita, M; Schols, D; Stevens, M; Tabarrini, O; Verbeken, E | 1 |
| Correll, T; Klibanov, OM | 1 |
| Miller, M | 1 |
| Chaisson, RE; Moore, RD; Styrt, BA | 1 |
| Cecchetti, V; Cruciani, G; Filipponi, E; Fravolini, A; Tabarrini, O | 1 |
| Evans, TG; Riley, D | 1 |
| Catalán, S; Chaves, F; de Rafael, L; Dronda, F | 1 |
| Archambaud, M; Clavé, D; Massip, P; Moatti, N; Rouquet, RM | 1 |
50 review(s) available for carbostyril and HIV Coinfection
| Article | Year |
|---|---|
Meta-analysis and systematic review of the efficacy and resistance for human immunodeficiency virus type 1 integrase strand transfer inhibitors.
Topics: Amides; Drug Resistance, Viral; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV Integrase; HIV Integrase Inhibitors; HIV-1; Humans; Microbial Sensitivity Tests; Oxazines; Piperazines; Pyridones; Quinolones; Raltegravir Potassium; Virus Replication | 2019 |
HIV-1 integrase strand transfer inhibitors: a review of current drugs, recent advances and drug resistance.
Topics: Amides; Anti-Retroviral Agents; Drug Resistance, Viral; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase; HIV Integrase Inhibitors; HIV-1; Humans; Oxazines; Piperazines; Pyridones; Quinolones; Raltegravir Potassium; Virus Replication | 2021 |
A Review of the Efficacy and Safety of Genvoya® (Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide) in the Management of HIV-1 Infection.
Topics: Anti-HIV Agents; Clinical Trials, Phase III as Topic; Cobicistat; Diarrhea; Disease Management; Drug Combinations; Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Emtricitabine; Headache; HIV Infections; HIV-1; Humans; Nausea; Quinolones; Randomized Controlled Trials as Topic; Tenofovir; Treatment Outcome | 2018 |
Cobicistat Versus Ritonavir: Similar Pharmacokinetic Enhancers But Some Important Differences.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Cobicistat; Darunavir; Drug Interactions; HIV Infections; Humans; Quinolones; Ritonavir | 2017 |
Pharmacokinetics of HIV-Integrase Inhibitors During Pregnancy: Mechanisms, Clinical Implications and Knowledge Gaps.
Topics: Amides; Anti-Retroviral Agents; Female; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV Integrase Inhibitors; HIV-1; Humans; Infectious Disease Transmission, Vertical; Knowledge; Oxazines; Piperazines; Pregnancy; Pyridones; Quinolones; Raltegravir Potassium | 2019 |
Clinical Impact of Virological Failure and Resistance Analysis Definitions used in Pivotal Clinical Trials of Initial Antiretroviral Treatment: A Systematic Review
Topics: Amides; Anti-Retroviral Agents; Clinical Trials as Topic; Cobicistat; Darunavir; Drug Resistance, Viral; Genotype; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Oxazines; Piperazines; Pyridones; Quinolones; Rilpivirine; RNA, Viral; Triazoles; Viral Load | 2018 |
A Review on Quinoline Derived Scaffolds as Anti-HIV Agents.
Topics: Animals; Anti-HIV Agents; Drug Discovery; HIV; HIV Infections; HIV Integrase; HIV Integrase Inhibitors; Humans; Models, Molecular; Quinolones | 2019 |
An evaluation of elvitegravir plus cobicistat plus tenofovir alafenamide plus emtricitabine as a single-tablet regimen for the treatment of HIV in children and adolescents.
Topics: Adenine; Adolescent; Alanine; Anti-HIV Agents; Child; Cobicistat; Emtricitabine; HIV Infections; Humans; Quinolones; Tablets; Tenofovir; United States; United States Food and Drug Administration | 2019 |
Next-generation integrase inhibitors : where to after raltegravir?
Topics: Clinical Trials as Topic; Drug Discovery; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; Humans; Oxazines; Piperazines; Pyridones; Pyrrolidinones; Quinolones; Raltegravir Potassium | 2013 |
Single-tablet regimens in HIV: does it really make a difference?
Topics: Adenine; Anti-HIV Agents; Carbamates; Cobicistat; Deoxycytidine; Drug Administration Schedule; Drug Combinations; Emtricitabine; HIV Infections; HIV-1; Humans; Nitriles; Organophosphonates; Pyrimidines; Quinolones; Reverse Transcriptase Inhibitors; Rilpivirine; Tablets; Tenofovir; Thiazoles | 2014 |
Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate single-tablet regimen (Stribild®): a review of its use in the management of HIV-1 infection in adults.
Topics: Adenine; Anti-HIV Agents; Carbamates; Deoxycytidine; Drug Combinations; Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; HIV Infections; HIV-1; Humans; Organophosphonates; Quinolones; Tablets; Thiazoles | 2014 |
Elvitegravir: a review of its use in adults with HIV-1 infection.
Topics: Adult; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; HIV Infections; HIV Integrase Inhibitors; HIV-1; Humans; Quinolones | 2014 |
Dolutegravir for the treatment of adult patients with HIV-1 infection.
Topics: Adult; Clinical Trials as Topic; Dideoxynucleosides; Drug Administration Schedule; Drug Combinations; Drug Interactions; Drug Resistance, Viral; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase; HIV Integrase Inhibitors; HIV-1; Humans; Lamivudine; Oxazines; Piperazines; Pyridones; Pyrrolidinones; Quinolones; Raltegravir Potassium | 2014 |
Which patients have greatest need for elvitegravir/cobicistat/ emtricitabine/tenofovirDF-based therapy?
Topics: Adenine; Anti-HIV Agents; Carbamates; Cobicistat; Deoxycytidine; Drug Combinations; Emtricitabine; HIV Infections; HIV-1; Humans; Patents as Topic; Phosphorous Acids; Quinolones; Thiazoles | 2014 |
Resistance analyses of integrase strand transfer inhibitors within phase 3 clinical trials of treatment-naive patients.
Topics: Clinical Trials, Phase III as Topic; Drug Resistance, Viral; Drug Therapy, Combination; Endpoint Determination; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase; HIV Integrase Inhibitors; HIV-1; Humans; Male; Oxazines; Piperazines; Pyridones; Pyrrolidinones; Quinolones; Raltegravir Potassium; Treatment Outcome; Viral Load | 2014 |
The pharmacokinetics, pharmacodynamics and clinical efficacy of elvitegravir + cobicistat + emtricitabine + tenofovir combination therapy for the treatment of HIV.
Topics: Adenine; Adult; Anti-HIV Agents; Carbamates; Deoxycytidine; Drug Approval; Drug Combinations; Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; European Union; HIV Infections; HIV-1; Humans; Organophosphonates; Quinolones; Tablets; Thiazoles | 2015 |
Stribild: a review of component characteristics and combination drug efficacy.
Topics: Adenine; Anti-HIV Agents; Carbamates; Deoxycytidine; Drug Combinations; Drug Synergism; Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; HIV Infections; Humans; Organophosphonates; Quinolones; Thiazoles | 2015 |
[Resistance profile and genetic barrier of dolutegravir].
Topics: Amino Acid Substitution; Clinical Trials as Topic; Drug Resistance, Multiple, Viral; Drug Resistance, Viral; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; HIV-1; Humans; Mutation, Missense; Oxazines; Piperazines; Point Mutation; Pyridones; Quinolones; Raltegravir Potassium; Virus Replication | 2015 |
HIV integrase inhibitors: a new era in the treatment of HIV.
Topics: Clinical Trials as Topic; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; Humans; Oxazines; Piperazines; Pyridones; Pyrrolidinones; Quinolones; Raltegravir Potassium | 2015 |
Use of Integrase Inhibitors in HIV-Infected Children and Adolescents.
Topics: Adolescent; Adult; Age Factors; Child; Drug Approval; Drug Resistance, Viral; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; Humans; Oxazines; Piperazines; Pyridones; Quinolones; Raltegravir Potassium | 2015 |
Cobicistat: Review of a Pharmacokinetic Enhancer for HIV Infection.
Topics: Anti-HIV Agents; Cobicistat; Cytochrome P-450 CYP3A Inhibitors; Darunavir; Drug Interactions; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Quinolones | 2015 |
Elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide for the treatment of HIV in adults.
Topics: Anti-HIV Agents; Bone Density; Clinical Trials as Topic; Cobicistat; Drug Combinations; Drug Resistance, Viral; Emtricitabine; HIV Infections; Humans; Quinolones; Tablets; Tenofovir | 2016 |
HIV pharmacotherapy: A review of integrase inhibitors.
Topics: Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; Humans; Oxazines; Piperazines; Pyridones; Quinolones; Raltegravir Potassium; Randomized Controlled Trials as Topic | 2016 |
Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide: A Review in HIV-1 Infection.
Topics: Adenine; Adolescent; Adult; Alanine; Anti-HIV Agents; Clinical Trials, Phase III as Topic; Cobicistat; Drug Combinations; Emtricitabine; HIV Infections; HIV-1; Humans; Quinolones; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Tenofovir | 2016 |
Renal effects of novel antiretroviral drugs.
Topics: Adenine; Alanine; Anti-HIV Agents; Atazanavir Sulfate; Cobicistat; Creatinine; Disease Progression; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Oxazines; Piperazines; Proteinuria; Pyridones; Quinolones; Raltegravir Potassium; Renal Insufficiency, Chronic; Tenofovir | 2017 |
Comparative Clinical Pharmacokinetics and Pharmacodynamics of HIV-1 Integrase Strand Transfer Inhibitors.
Topics: Anti-Retroviral Agents; Area Under Curve; Coinfection; Cytochrome P-450 CYP3A; Drug Combinations; Drug Interactions; Female; Half-Life; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase; HIV Integrase Inhibitors; Humans; Liver Failure; Metabolic Clearance Rate; Oxazines; Piperazines; Pregnancy; Protein Binding; Pyridones; Quinolones; Raltegravir Potassium; Renal Insufficiency | 2017 |
Differences among HIV-1 subtypes in drug resistance against integrase inhibitors.
Topics: Drug Resistance, Viral; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; HIV-1; Humans; Oxazines; Piperazines; Pyridones; Quinolones; Raltegravir Potassium | 2016 |
Therapy-Emergent Drug Resistance to Integrase Strand Transfer Inhibitors in HIV-1 Patients: A Subgroup Meta-Analysis of Clinical Trials.
Topics: Clinical Trials as Topic; Drug Resistance, Viral; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; HIV-1; Humans; Oxazines; Piperazines; Pyridones; Quinolones; Raltegravir Potassium; Virus Replication | 2016 |
Elvitegravir for the treatment of HIV.
Topics: Anti-HIV Agents; Clinical Trials as Topic; Cobicistat; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Quinolones; Ritonavir; Treatment Outcome | 2016 |
How recent findings on the pharmacokinetics and pharmacodynamics of integrase inhibitors can inform clinical use.
Topics: Cobicistat; Drug Interactions; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; HIV-1; Humans; Oxazines; Piperazines; Pyridones; Quinolones; Raltegravir Potassium; Viral Load | 2017 |
Emerging therapies for hepatitis C and HIV in drug abusers: drugs and strategies.
Topics: Anti-Retroviral Agents; Antiviral Agents; Comorbidity; Hepatitis C, Chronic; HIV Infections; Humans; Pyrimidine Nucleosides; Pyrrolidinones; Quinolones; Raltegravir Potassium; Substance Abuse, Intravenous | 2008 |
Integrase inhibitors: a clinical review of raltegravir and elvitegravir.
Topics: Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Drug Interactions; Drug Resistance, Viral; Drug Therapy, Combination; HIV; HIV Infections; HIV Integrase; HIV Protease Inhibitors; Humans; Pyrrolidinones; Quinolones; Raltegravir Potassium | 2008 |
Raltegravir, elvitegravir, and metoogravir: the birth of "me-too" HIV-1 integrase inhibitors.
Topics: Antiviral Agents; Drug Discovery; HIV Infections; HIV Integrase; HIV Integrase Inhibitors; HIV-1; Humans; Pyrrolidinones; Quinolones; Raltegravir Potassium | 2009 |
Targeting the HIV integration process in antiviral therapy.
Topics: HIV; HIV Infections; HIV Integrase Inhibitors; Humans; Pyrrolidinones; Quinolones; Raltegravir Potassium; Virus Integration | 2008 |
Tuberculosis in people with HIV.
Topics: Disease Progression; HIV Infections; Humans; Meta-Analysis as Topic; Quinolones; Survival Analysis; Time Factors; Tuberculosis; United States Food and Drug Administration | 2007 |
[Resistance to integrase inhibitors].
Topics: Amino Acid Substitution; Clinical Trials as Topic; Drug Resistance, Multiple, Viral; Drug Resistance, Viral; Genetic Variation; HIV; HIV Infections; HIV Integrase; HIV Integrase Inhibitors; Humans; Models, Molecular; Mutation, Missense; Point Mutation; Protein Conformation; Pyrrolidinones; Quinolones; Raltegravir Potassium | 2008 |
Integrase inhibitors: a novel class of antiretroviral agents.
Topics: Anti-HIV Agents; HIV Infections; Humans; Integrase Inhibitors; Pyrrolidinones; Quinolones; Raltegravir Potassium | 2010 |
Integrase inhibitors in salvage therapy regimens for HIV-1 infection.
Topics: HIV Infections; HIV Integrase Inhibitors; HIV-1; Humans; Quinolones; Salvage Therapy | 2009 |
Clinical pharmacokinetic and pharmacodynamic profile of the HIV integrase inhibitor elvitegravir.
Topics: Animals; Drug Interactions; Drug Therapy, Combination; HIV Infections; HIV Integrase Inhibitors; Humans; Quinolones | 2011 |
Elvitegravir: a once-daily, boosted, HIV-1 integrase inhibitor.
Topics: Adenine; Carbamates; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Drug Combinations; Drug Interactions; Drug Resistance, Viral; Drug-Related Side Effects and Adverse Reactions; Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; HIV Infections; HIV Integrase Inhibitors; HIV-1; Humans; Organophosphonates; Quinolones; Randomized Controlled Trials as Topic; Thiazoles | 2012 |
Elvitegravir: a once-daily inhibitor of HIV-1 integrase.
Topics: Anti-HIV Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Administration Schedule; Drug Combinations; Drug Resistance, Viral; Drug Therapy, Combination; HIV Infections; HIV Integrase Inhibitors; Humans; Quinolones | 2012 |
Update on raltegravir and the development of new integrase strand transfer inhibitors.
Topics: Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; Humans; Oxazines; Piperazines; Pyridones; Pyrrolidinones; Quinolones; Raltegravir Potassium | 2012 |
The use of HIV-1 integrase inhibitors in antiretroviral naive patients.
Topics: Antiretroviral Therapy, Highly Active; Clinical Trials as Topic; Coinfection; Hepatitis C; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; Humans; Oxazines; Piperazines; Pyridones; Pyrrolidinones; Quinolones; Raltegravir Potassium; Treatment Outcome | 2012 |
Pharmacology of HIV integrase inhibitors.
Topics: Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; HIV-1; Humans; Oxazines; Piperazines; Pyridones; Pyrrolidinones; Quinolones; Raltegravir Potassium; United States | 2012 |
Combinational therapies for HIV: a focus on EVG/COBI/FTC/TDF.
Topics: Adenine; Anti-HIV Agents; Carbamates; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cobicistat; Deoxycytidine; Drug Combinations; Drug Resistance, Multiple, Viral; Emtricitabine; HIV Infections; Humans; Organophosphonates; Quinolones; Tenofovir; Thiazoles | 2012 |
HIV integrase inhibitors in ART-experienced patients.
Topics: Antiretroviral Therapy, Highly Active; Clinical Trials as Topic; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; Humans; Oxazines; Piperazines; Pyridones; Pyrrolidinones; Quinolones; Raltegravir Potassium; Salvage Therapy; Treatment Outcome | 2012 |
Tolerability of HIV integrase inhibitors.
Topics: Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug-Related Side Effects and Adverse Reactions; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; Humans; Kidney; Lipid Metabolism; Oxazines; Piperazines; Pyridones; Pyrrolidinones; Quinolones; Raltegravir Potassium | 2012 |
Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate single tablet for HIV-1 infection treatment.
Topics: Adenine; Anti-HIV Agents; Carbamates; Clinical Trials, Phase III as Topic; Deoxycytidine; Drug Combinations; Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; HIV Infections; HIV Integrase Inhibitors; Humans; Organophosphonates; Quinolones; Tablets; Thiazoles; Viral Load | 2012 |
Cobicistat-boosted elvitegravir-based fixed-dose combination antiretroviral therapy for HIV infection.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Carbamates; Cobicistat; Drug Approval; Drug Combinations; Drug Interactions; Drug Resistance, Viral; HIV Infections; HIV Integrase Inhibitors; Humans; Patient Safety; Quinolones; Thiazoles | 2012 |
Integrase inhibitors: a new treatment option for patients with human immunodeficiency virus infection.
Topics: Dose-Response Relationship, Drug; HIV Infections; HIV Integrase Inhibitors; Humans; Organic Chemicals; Pyrrolidinones; Quinolones; Raltegravir Potassium; Randomized Controlled Trials as Topic | 2008 |
38 trial(s) available for carbostyril and HIV Coinfection
| Article | Year |
|---|---|
Safety and efficacy of elvitegravir, dolutegravir, and raltegravir in a real-world cohort of treatment-naïve and -experienced patients.
Topics: Adult; Aged; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; Humans; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Quinolones; Raltegravir Potassium; Retrospective Studies; Viral Load; Young Adult | 2019 |
Bone mineral density in virologically suppressed people aged 60 years or older with HIV-1 switching from a regimen containing tenofovir disoproxil fumarate to an elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide single-tablet regimen: a m
Topics: Adenine; Aged; Aged, 80 and over; Alanine; Anti-HIV Agents; Bone Density; Cobicistat; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Quinolones; Tablets; Tenofovir | 2019 |
Elvitegravir-Cobicistat-Emtricitabine-Tenofovir Alafenamide Single-tablet Regimen for Human Immunodeficiency Virus Postexposure Prophylaxis.
Topics: Adenine; Alanine; Anti-HIV Agents; Cobicistat; Drug Combinations; Emtricitabine; HIV Infections; HIV-1; Humans; Quinolones; Tablets; Tenofovir | 2020 |
Switching to the single-tablet regimen of elvitegravir, cobicistat, emtricitabine, and tenofovir DF from non-nucleoside reverse transcriptase inhibitor plus coformulated emtricitabine and tenofovir DF regimens: Week 96 results of STRATEGY-NNRTI.
Topics: Adult; Antiretroviral Therapy, Highly Active; Cobicistat; Drug Combinations; Drug Substitution; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Patient Reported Outcome Measures; Quinolones; Tablets; Tenofovir; Time Factors; Treatment Outcome | 2017 |
Week 48 resistance analysis of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF versus Atazanavir + Ritonavir + Emtricitabine/Tenofovir DF in HIV-1 infected women (WAVES study GS-US-236-0128).
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cobicistat; Drug Resistance, Viral; Emtricitabine; Female; Genotype; HIV Infections; HIV-1; Humans; Microbial Sensitivity Tests; Mutation; Quinolones; Sequence Analysis, DNA; Tenofovir; Time Factors; Treatment Failure; Treatment Outcome; Viral Load | 2017 |
Tenofovir disoproxil fumarate/emtricitabine plus ritonavir-boosted lopinavir or cobicistat-boosted elvitegravir as a single-tablet regimen for HIV post-exposure prophylaxis.
Topics: Adult; Anti-HIV Agents; Cobicistat; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Lopinavir; Male; Medication Adherence; Post-Exposure Prophylaxis; Prospective Studies; Quinolones; Reverse Transcriptase Inhibitors; Ritonavir; Tablets; Tenofovir | 2017 |
HIV treatment simplification to elvitegravir/cobicistat/emtricitabine/tenofovir disproxil fumarate (E/C/F/TDF) plus darunavir: a pharmacokinetic study.
Topics: Adult; Aged; Anti-HIV Agents; Cobicistat; Darunavir; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Integrase Inhibitors; Male; Middle Aged; Protease Inhibitors; Quinolones; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Viral Load | 2017 |
Superior Efficacy and Improved Renal and Bone Safety After Switching from a Tenofovir Disoproxil Fumarate- to a Tenofovir Alafenamide-Based Regimen Through 96 Weeks of Treatment.
Topics: Adenine; Alanine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Bone Density; Cobicistat; Drug Combinations; Drug Substitution; Emtricitabine; HIV Infections; HIV-1; Humans; Kidney; Quinolones; RNA, Viral; Tenofovir; Treatment Outcome | 2018 |
Brief Report: Efficacy and Safety of Switching to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide (E/C/F/TAF) in Virologically Suppressed Women.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cobicistat; Double-Blind Method; Drug Combinations; Drug Resistance, Viral; Drug-Related Side Effects and Adverse Reactions; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Integrase Inhibitors; Protease Inhibitors; Quinolones; RNA, Viral; Tenofovir | 2018 |
Elvitegravir/cobicistat pharmacokinetics in pregnant and postpartum women with HIV.
Topics: Administration, Oral; Adult; Anti-HIV Agents; Chromatography, Liquid; Cobicistat; Female; HIV Infections; Humans; Infant, Newborn; Middle Aged; Plasma; Postpartum Period; Pregnancy; Pregnancy Complications, Infectious; Prospective Studies; Quinolones; Tandem Mass Spectrometry; United States; Young Adult | 2018 |
Seminal Tenofovir Concentrations, Viral Suppression, and Semen Quality With Tenofovir Alafenamide, Compared With Tenofovir Disoproxil Fumarate (Spanish HIV/AIDS Research Network, PreEC/RIS 40).
Topics: Adenine; Adult; Alanine; Anti-Retroviral Agents; Cobicistat; Emtricitabine; HIV Infections; HIV-1; Humans; Male; Middle Aged; Prospective Studies; Quinolones; RNA, Viral; Semen; Semen Analysis; Tenofovir | 2019 |
A randomized phase 3 study comparing once-daily elvitegravir with twice-daily raltegravir in treatment-experienced subjects with HIV-1 infection: 96-week results.
Topics: Double-Blind Method; Drug Resistance, Viral; Drug Therapy, Combination; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; HIV-1; Humans; Longitudinal Studies; Pyrrolidinones; Quinolones; Raltegravir Potassium; Ritonavir; RNA, Viral; Viral Load | 2013 |
Dolutegravir in antiretroviral-experienced patients with raltegravir- and/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study.
Topics: Adult; Anti-HIV Agents; Drug Resistance, Viral; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Male; Middle Aged; Oxazines; Pilot Projects; Piperazines; Pyridones; Pyrrolidinones; Quinolones; Raltegravir Potassium; RNA, Viral; Viral Load | 2014 |
Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week results o
Topics: Adenine; Adult; Anti-HIV Agents; Carbamates; Cobicistat; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Female; HIV; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Protease Inhibitors; Quinolones; Ritonavir; Tenofovir; Thiazoles; Viral Load | 2014 |
Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week r
Topics: Adenine; Adult; Anti-HIV Agents; Carbamates; Cobicistat; Deoxycytidine; Emtricitabine; Female; HIV; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Quinolones; Reverse Transcriptase Inhibitors; Tenofovir; Thiazoles; Viral Load | 2014 |
Week 144 resistance analysis of elvitegravir/cobicistat/emtricitabine/tenofovir DF versus efavirenz/emtricitabine/tenofovir DF in antiretroviral-naive patients.
Topics: Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Cobicistat; Cyclopropanes; Drug Resistance, Viral; Emtricitabine; Female; Genotype; HIV Infections; HIV-1; Humans; Male; Microbial Sensitivity Tests; Mutation; Quinolones; Tenofovir; Time Factors; Treatment Outcome; Viral Load | 2015 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Arthralgia; Bone Density; Carbamates; CD4 Lymphocyte Count; Cobicistat; Deoxycytidine; Double-Blind Method; Drug Combinations; Emtricitabine; Female; Headache; HIV Infections; Humans; Kidney; Male; Nausea; Organophosphonates; Quinolones; Respiration Disorders; Sleep Initiation and Maintenance Disorders; Tenofovir; Thiazoles; Treatment Outcome; Viral Load | 2015 |
Patient-Reported Symptoms Over 48 Weeks in a Randomized, Open-Label, Phase IIIb Non-Inferiority Trial of Adults with HIV Switching to Co-Formulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir DF versus Continuation of Non-Nucleoside Reverse Tra
Topics: Adult; Anti-HIV Agents; Cobicistat; Drug Combinations; Emtricitabine; Female; HIV Infections; Humans; Male; Middle Aged; Patient Outcome Assessment; Quality of Life; Quinolones; Tenofovir | 2015 |
Population Pharmacokinetics of Boosted-Elvitegravir in HIV-Infected Patients.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Child; Drug Therapy, Combination; Female; HIV Infections; HIV Integrase; HIV Integrase Inhibitors; Humans; Male; Middle Aged; Quinolones; Young Adult | 2016 |
Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Patients With Renal Impairment: 48-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study.
Topics: Adult; Albuminuria; Bone Density; Cobicistat; Drug Substitution; Drug Therapy, Combination; Emtricitabine; Female; Glomerular Filtration Rate; HIV Infections; Humans; Male; Middle Aged; Proteinuria; Quinolones; Renal Insufficiency; Tenofovir | 2016 |
Brief Report: A Randomized, Double-Blind Comparison of Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate, Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine for Initial HIV-1 Treatment: Week 96 Results.
Topics: Adenine; Alanine; Albuminuria; Anti-HIV Agents; Bone Density; CD4 Lymphocyte Count; Cobicistat; Double-Blind Method; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Proteinuria; Quinolones; RNA, Viral; Tenofovir | 2016 |
Rare emergence of drug resistance in HIV-1 treatment-naïve patients after 48 weeks of treatment with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; CD4 Lymphocyte Count; Cobicistat; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Quinolones; Tenofovir; Young Adult | 2016 |
Brief Report: Efficacy and Safety of Switching to a Single-Tablet Regimen of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1/Hepatitis B-Coinfected Adults.
Topics: Adenine; Alanine; Anti-HIV Agents; Cobicistat; Coinfection; Drug Combinations; Drug Substitution; Emtricitabine; Female; Hepatitis B; HIV Infections; Humans; Male; Middle Aged; Quinolones; Tenofovir; Treatment Outcome | 2016 |
An Indirect Comparison of Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate and Abacavir/Lamivudine + Dolutegravir in Initial Therapy.
Topics: Adult; Algorithms; Anti-HIV Agents; Cobicistat; Dideoxynucleosides; Drug Combinations; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Male; Oxazines; Patient Safety; Piperazines; Pyridones; Quinolones; Risk; Tenofovir | 2016 |
Integrase inhibitor versus protease inhibitor based regimen for HIV-1 infected women (WAVES): a randomised, controlled, double-blind, phase 3 study.
Topics: Adult; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Cobicistat; Double-Blind Method; Emtricitabine; Female; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; Humans; International Cooperation; Quinolones; Ritonavir; RNA, Viral; Tenofovir; Viral Load | 2016 |
Safety, efficacy, and pharmacokinetics of a single-tablet regimen containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in treatment-naive, HIV-infected adolescents: a single-arm, open-label trial.
Topics: Adenine; Adolescent; Alanine; Anti-HIV Agents; Area Under Curve; CD4 Lymphocyte Count; Child; Cobicistat; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Lost to Follow-Up; Male; Quinolones; RNA, Viral; South Africa; Tablets; Tenofovir; Thailand; Uganda; United States; Viral Load | 2016 |
Switch as maintenance to elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate: week 48 results in a clinical cohort.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cobicistat; Cohort Studies; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Maintenance Chemotherapy; Male; Middle Aged; Polymerase Chain Reaction; Quinolones; RNA, Viral; Tablets; Tenofovir; Viral Load; Viremia | 2017 |
Brief Report: Randomized, Double-Blind Comparison of Tenofovir Alafenamide (TAF) vs Tenofovir Disoproxil Fumarate (TDF), Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine (E/C/F) for Initial HIV-1 Treatment: Week 144 Results.
Topics: Adenine; Alanine; Anti-HIV Agents; Bone Density; CD4 Lymphocyte Count; Cobicistat; Double-Blind Method; Emtricitabine; HIV Infections; Humans; Middle Aged; Quinolones; Tenofovir; Treatment Outcome; United States | 2017 |
Phase III trial begins for elvitegravir.
Topics: Double-Blind Method; HIV Infections; HIV Integrase Inhibitors; Humans; Quinolones; Viral Load | 2008 |
Activity of elvitegravir, a once-daily integrase inhibitor, against resistant HIV Type 1: results of a phase 2, randomized, controlled, dose-ranging clinical trial.
Topics: Adolescent; Adult; Aged; CD4 Lymphocyte Count; Darunavir; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Pyridines; Pyrones; Quinolones; Ritonavir; RNA, Viral; Sulfonamides; Treatment Outcome; Young Adult | 2010 |
Pharmacokinetics and bioavailability of an integrase and novel pharmacoenhancer-containing single-tablet fixed-dose combination regimen for the treatment of HIV.
Topics: Adenine; Administration, Oral; Adult; Anti-HIV Agents; Biological Availability; Deoxycytidine; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV Integrase; HIV Integrase Inhibitors; Humans; Male; Organophosphonates; Plasma; Quinolones; Tablets; Tenofovir | 2010 |
Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; CD4 Lymphocyte Count; Cobicistat; Cyclopropanes; Deoxycytidine; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Organophosphonates; Patient Compliance; Patient Selection; Quinolones; Tenofovir; Thiazoles; Treatment Outcome | 2011 |
Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study.
Topics: Adult; Alanine Transaminase; Anti-Retroviral Agents; Aspartate Aminotransferases; Atazanavir Sulfate; CD4 Lymphocyte Count; Diarrhea; Double-Blind Method; Drug Therapy, Combination; Female; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Middle Aged; Oligopeptides; Pyridines; Pyrrolidinones; Quinolones; Raltegravir Potassium; Ritonavir; RNA, Viral; Treatment Outcome; Viral Load | 2012 |
Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-
Topics: Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; Carbamates; Cobicistat; Deoxycytidine; Double-Blind Method; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Oligopeptides; Organophosphonates; Pyridines; Quinolones; Ritonavir; Tenofovir; Thiazoles | 2012 |
Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; Cobicistat; Cyclopropanes; Deoxycytidine; Double-Blind Method; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Organophosphonates; Quinolones; Tenofovir; Thiazoles | 2012 |
A randomized, double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir DF vs ritonavir-boosted atazanavir plus coformulated emtricitabine and tenofovir DF for initial treatment of HIV-1 infection: analysis of week 96 results
Topics: Adenine; Adult; Alanine Transaminase; Anti-HIV Agents; Aspartate Aminotransferases; Atazanavir Sulfate; Bilirubin; Bone Density; Carbamates; Cobicistat; Confidence Intervals; Creatinine; Deoxycytidine; Double-Blind Method; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Oligopeptides; Organophosphonates; Pyridines; Quinolones; Ritonavir; RNA, Viral; Tenofovir; Thiazoles; Triglycerides | 2013 |
A randomized double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: analysis of week 96 results.
Topics: Adenine; Adult; Anti-HIV Agents; Carbamates; Creatinine; Deoxycytidine; Double-Blind Method; Drug Combinations; Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Female; HIV Infections; HIV-1; Humans; Male; Organophosphonates; Oxazines; Quinolones; RNA, Viral; Thiazoles; Treatment Outcome; Young Adult | 2013 |
Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naive and treatment-experienced patients.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Enzyme Inhibitors; HIV Infections; HIV Integrase; Humans; Quinolones | 2006 |
157 other study(ies) available for carbostyril and HIV Coinfection
| Article | Year |
|---|---|
Durability of Integrase STrand Inhibitor (InSTI)-based regimen in geriatric people living with HIV in the GEPPO cohort.
Topics: Aged; Amides; Anti-Retroviral Agents; Drug Therapy, Combination; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; Humans; Longitudinal Studies; Male; Medication Adherence; Oxazines; Piperazines; Polypharmacy; Proportional Hazards Models; Prospective Studies; Pyridones; Quinolones; Raltegravir Potassium; Treatment Outcome | 2021 |
Switching from efavirenz to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide reduces central nervous system symptoms in people living with HIV.
Topics: Adenine; Adult; Alanine; Alkynes; Anti-HIV Agents; Benzoxazines; Central Nervous System; Cobicistat; Cyclopropanes; Drug Combinations; Emtricitabine; Female; HIV Infections; Humans; Male; Prospective Studies; Quality of Life; Quinolones; Sleep Quality; Tenofovir | 2021 |
Incidence of low-level viremia and its impact on virologic failure among people living with HIV-1 who switched to elvitegravir-based antiretroviral therapy.
Topics: Anti-HIV Agents; Emtricitabine; HIV Infections; HIV-1; Humans; Incidence; Quinolones; Raltegravir Potassium; Retrospective Studies; Viremia | 2022 |
Effectiveness and safety of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate single-tablet combination among HIV-infected patients in Turkey: results from a real world setting.
Topics: Adult; Anti-HIV Agents; Cobicistat; Drug Combinations; Emtricitabine; HIV Infections; Homosexuality, Male; Humans; Male; Quinolones; Retrospective Studies; Tablets; Tenofovir; Turkey | 2021 |
A 28-Year-Old Man With Diffuse Bilateral Pulmonary Nodules.
Topics: Adult; Anti-HIV Agents; Child; Cobicistat; Drug Combinations; Emtricitabine; HIV Infections; Humans; Male; Quinolones; Tenofovir | 2022 |
High-level dolutegravir resistance can emerge rapidly from few variants and spread by recombination: implications for integrase strand transfer inhibitor salvage therapy.
Topics: Drug Resistance, Viral; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase; HIV Integrase Inhibitors; HIV-1; Humans; Mutation; Oxazines; Piperazines; Pyridones; Quinolones; Recombination, Genetic; Salvage Therapy | 2022 |
Dolutegravir in Pregnancy as Compared with Current HIV Regimens in the United States.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Cobicistat; Cohort Studies; Darunavir; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Infant, Newborn; Oxazines; Piperazines; Pregnancy; Premature Birth; Pyridones; Quinolones; Raltegravir Potassium; Rilpivirine; Ritonavir; United States | 2022 |
Higher Risk of Dyslipidemia With Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide than Efavirenz, Lamivudine, and Tenofovir Disoproxil Fumarate Among Antiretroviral-Naive People Living With HIV in China.
Topics: Adenine; Alanine; Alkynes; Anti-HIV Agents; Anti-Retroviral Agents; Benzoxazines; Cholesterol, LDL; Cobicistat; Cyclopropanes; Emtricitabine; HIV Infections; HIV-1; Humans; Hypercholesterolemia; Hypertriglyceridemia; Lamivudine; Lipoproteins, HDL; Quinolones; Retrospective Studies; Tenofovir | 2022 |
Switching to Tenofovir Alafenamide in Elvitegravir-Based Regimens: Pharmacokinetics and Antiviral Activity in Cerebrospinal Fluid.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Emtricitabine; HIV Infections; Humans; Quinolones; Tenofovir | 2020 |
Switching antiretrovirals in older patients.
Topics: Adenine; Aged; Alanine; Bone Density; Cobicistat; Emtricitabine; HIV Infections; HIV-1; Humans; Middle Aged; Quinolones; Tablets; Tenofovir | 2019 |
Impact of NRTI resistance mutations on virological effectiveness of antiretroviral regimens containing elvitegravir: a multi-cohort study.
Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Cohort Studies; Databases, Factual; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Italy; Male; Middle Aged; Mutation; Quinolones; Treatment Outcome; Viral Load | 2020 |
Comparable
Topics: Amides; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV Integrase Inhibitors; HIV-1; Humans; Mutation; Oxazines; Piperazines; Pyridones; Quinolones; Raltegravir Potassium | 2019 |
Fevers and Night Sweats in a 35-year-old Man With Recent Travel to Southeast Asia.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Asia, Southeastern; Cobicistat; Emtricitabine; HIV Infections; Humans; Laos; Male; Quinolones; Sweating; Tenofovir; Thailand; Travel; United States | 2019 |
The impact of integrase inhibitor-based regimens on markers of inflammation among HIV naïve patients.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Cytokines; Drug Therapy, Combination; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; HIV-1; Humans; Inflammation; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Quinolones; Raltegravir Potassium | 2020 |
Brief Report: Integrase Strand Transfer Inhibitors Are Associated With Lower Risk of Incident Cardiovascular Disease in People Living With HIV.
Topics: Adult; Anti-Retroviral Agents; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; Humans; Ischemic Stroke; Male; Middle Aged; Myocardial Infarction; Oxazines; Piperazines; Pyridones; Quinolones; Raltegravir Potassium; Retrospective Studies | 2020 |
Clinically Significant Lower Elvitegravir Exposure During the Third Trimester of Pregnant Patients Living With Human Immunodeficiency Virus: Data From the Pharmacokinetics of ANtiretroviral agents in HIV-infected pregNAnt women (PANNA) Network.
Topics: Anti-HIV Agents; Anti-Retroviral Agents; Female; HIV Infections; Humans; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Trimester, Third; Pregnant Women; Quinolones | 2020 |
Molecular dynamic simulations to investigate the structural impact of known drug resistance mutations on HIV-1C Integrase-Dolutegravir binding.
Topics: Amino Acid Sequence; Catalytic Domain; Drug Resistance, Viral; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase; HIV Integrase Inhibitors; HIV-1; Humans; Molecular Dynamics Simulation; Mutation; Oxazines; Piperazines; Protein Binding; Protein Stability; Pyridones; Quinolones; Raltegravir Potassium; South Africa; Virus Replication | 2020 |
Design, synthesis and SAR study of bridged tricyclic pyrimidinone carboxamides as HIV-1 integrase inhibitors.
Topics: Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; HIV Infections; HIV Integrase; HIV Integrase Inhibitors; HIV-1; Humans; Imidazoles; Mutation; Pyrrolidinones; Quinolones; Raltegravir Potassium; Structure-Activity Relationship | 2020 |
An Elvitegravir Nanoformulation Crosses the Blood-Brain Barrier and Suppresses HIV-1 Replication in Microglia.
Topics: Animals; Anti-HIV Agents; Anti-Retroviral Agents; Blood-Brain Barrier; Disease Models, Animal; Drug Carriers; Drug Delivery Systems; HIV Infections; HIV-1; Integrase Inhibitors; Macrophages; Male; Mice; Mice, Inbred NOD; Microglia; Nanoparticles; Pilot Projects; Plasma; Quinolones; Viral Load; Virus Replication | 2020 |
Susceptibility to HIV-1 integrase strand transfer inhibitors (INSTIs) in highly treatment-experienced patients who failed an INSTI-based regimen.
Topics: Amides; Drug Resistance, Multiple, Viral; Female; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV Integrase; HIV Integrase Inhibitors; HIV-1; Humans; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Quinolones; Raltegravir Potassium; Treatment Outcome | 2020 |
Effectiveness of the combination elvitegravir/cobicistat/tenofovir/emtricitabine (EVG/COB/TFV/FTC) plus darunavir among treatment-experienced patients in clinical practice: a multicentre cohort study.
Topics: Adult; Anti-HIV Agents; Cobicistat; Darunavir; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Quinolones; Spain; Tenofovir; Treatment Outcome; Viral Load | 2020 |
Single oral dose for HIV pre or post-exposure prophylaxis: user desirability and biological efficacy in macaques.
Topics: Adenine; Administration, Oral; Animals; Cross-Sectional Studies; Drug Combinations; Emtricitabine; HIV Infections; Homosexuality, Male; Humans; Macaca; Male; Patient Compliance; Pre-Exposure Prophylaxis; Quinolones; Rectum; Surveys and Questionnaires; Tenofovir | 2020 |
Impact of archived M184V/I mutation on the effectiveness of switch to co-formulated elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide among virally suppressed people living with HIV.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Cobicistat; Emtricitabine; HIV Infections; HIV-1; Humans; Mutation; Quinolones; Retrospective Studies; Tenofovir | 2020 |
Structural Comparison of Diverse HIV-1 Subtypes using Molecular Modelling and Docking Analyses of Integrase Inhibitors.
Topics: Amides; Binding Sites; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV Integrase; HIV Integrase Inhibitors; HIV-1; Humans; Linear Models; Models, Molecular; Molecular Docking Simulation; Oxazines; Piperazines; Pyridones; Quinolones; Raltegravir Potassium; Sequence Alignment | 2020 |
Differential effects of integrase strand transfer inhibitors, elvitegravir and raltegravir, on oligodendrocyte maturation: A role for the integrated stress response.
Topics: Animals; Cell Differentiation; Cuprizone; HIV Infections; Humans; Integrases; Mice; Mice, Inbred C57BL; Myelin Sheath; Oligodendroglia; Quinolones; Raltegravir Potassium; Rats | 2021 |
Second-generation integrase strand inhibitors can be effective against elvitegravir-derived multiple integrase gene substitutions.
Topics: Adult; Drug Resistance, Viral; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase; HIV Integrase Inhibitors; HIV-1; Humans; Integrases; Male; Pyridones; Quinolones; Raltegravir Potassium | 2020 |
Changes in neurocognitive assessment scores after initiating dolutegravir- versus elvitegravir-based antiretroviral therapy.
Topics: Adult; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; HIV-1; Humans; Male; Middle Aged; Oxazines; Piperazines; Prospective Studies; Pyridones; Quinolones | 2021 |
Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide discontinuation and return to normal weight.
Topics: Adult; Alanine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cobicistat; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Quinolones; Tenofovir; Weight Gain | 2021 |
Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide as Maintenance Treatment in HIV/HBV-Coinfected Patients.
Topics: Adult; Alanine; Anti-HIV Agents; Cobicistat; Cohort Studies; Drug Combinations; Drug Substitution; Emtricitabine; Female; Hepatitis B, Chronic; HIV Infections; HIV-1; Humans; Male; Middle Aged; Prospective Studies; Quinolones; Taiwan; Tenofovir | 2021 |
Preoperative rapid suppression of viral load by elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide regimen in human immunodeficiency virus-positive fracture patients significantly reduces postoperative complications.
Topics: Adenine; Alanine; Anti-HIV Agents; Cobicistat; Drug Combinations; Emtricitabine; HIV; HIV Infections; Humans; Postoperative Complications; Quinolones; Tenofovir; Viral Load | 2020 |
Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Adults With HIV and M184V/I Mutation.
Topics: Adult; Aged; Alanine; Anti-HIV Agents; Cobicistat; Drug Combinations; Drug Resistance, Viral; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Mutation; Quinolones; Tenofovir; Young Adult | 2021 |
Integrase Strand Transfer Inhibitor Start or Switch Impacts Learning in Women With HIV.
Topics: Adult; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase; HIV Integrase Inhibitors; Humans; Integrases; Middle Aged; Oxazines; Piperazines; Prospective Studies; Pyridones; Quinolones; Raltegravir Potassium; Reverse Transcriptase Inhibitors; United States | 2021 |
Hepatic Steatosis Associated With Exposure to Elvitegravir and Raltegravir.
Topics: HIV Infections; Humans; Prospective Studies; Quinolones; Raltegravir Potassium | 2021 |
Tolerability of integrase inhibitors in a real-life setting.
Topics: Adult; Cohort Studies; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; HIV-1; Humans; Life Style; Male; Medication Adherence; Middle Aged; Oxazines; Piperazines; Proportional Hazards Models; Pyridones; Quinolones; Raltegravir Potassium; Retrospective Studies | 2017 |
Efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate as treatment for primary or recent HIV infection-authors' response.
Topics: Adenine; Anti-HIV Agents; Cobicistat; Deoxycytidine; Emtricitabine; HIV Infections; Humans; Organophosphonates; Quinolones; Tenofovir | 2017 |
Right hip and bilateral shoulder capsulitis in an HIV-infected individual treated with elvitegravir and cobicistat.
Topics: Anti-HIV Agents; Bursitis; Cobicistat; Hip Joint; HIV Infections; Humans; Male; Middle Aged; Quinolones; Radionuclide Imaging; Shoulder Joint | 2017 |
HIV-1 integrase inhibitor resistance among treatment naïve patients in the West of Scotland.
Topics: Adult; Aged; Drug Resistance, Viral; Female; Genotype; HIV Infections; HIV Integrase; HIV Integrase Inhibitors; HIV-1; Humans; Male; Middle Aged; Mutation; Quinolones; Scotland; Treatment Outcome; Viral Load; Young Adult | 2017 |
Free and total plasma concentrations of elvitegravir/cobicistat during pregnancy and postpartum: a case report.
Topics: Adult; Anti-HIV Agents; Cobicistat; Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Female; HIV Infections; Humans; Postpartum Period; Pregnancy; Quinolones | 2017 |
High decay of blood HIV reservoir when tenofovir/emtricitabine/elvitegravir/cobicistat is initiated during the acute primary HIV infection.
Topics: Adult; Anti-HIV Agents; Blood; Cobicistat; Emtricitabine; HIV Infections; HIV-1; Humans; Male; Middle Aged; Quinolones; Secondary Prevention; Tenofovir; Treatment Outcome; Viral Load | 2017 |
Clinical Experience with the Integrase Inhibitors Dolutegravir and Elvitegravir in HIV-infected Patients: Efficacy, Safety and Tolerance.
Topics: Adult; Aged; Aged, 80 and over; Cobicistat; Dideoxynucleosides; Drug Combinations; Female; Follow-Up Studies; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; Humans; Lamivudine; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Quinolones; Retrospective Studies; Risk Factors; Spain; Treatment Outcome; Young Adult | 2017 |
Safety and tolerability of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil fumarate in a real life setting: Data from surveillance cohort long-term toxicity antiretrovirals/antivirals (SCOLTA) project.
Topics: Adult; Anti-HIV Agents; Cobicistat; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Maximum Tolerated Dose; Middle Aged; Quinolones; Safety; Tenofovir | 2017 |
Prevalence of drug-drug interactions in the era of HIV integrase inhibitors: a retrospective clinical study.
Topics: Adult; Anti-Retroviral Agents; Databases, Factual; Drug Interactions; Drug-Related Side Effects and Adverse Reactions; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; Humans; Male; Middle Aged; Oxazines; Piperazines; Prevalence; Pyridones; Quinolones; Retrospective Studies; Risk Factors | 2017 |
Degradable bioadhesive nanoparticles for prolonged intravaginal delivery and retention of elvitegravir.
Topics: Administration, Intravaginal; Animals; Anti-HIV Agents; Delayed-Action Preparations; Female; HIV; HIV Infections; Humans; Mice, Inbred C57BL; Nanoparticles; Quinolones; Vagina | 2017 |
HIV-1 non-group M phenotypic susceptibility to integrase strand transfer inhibitors.
Topics: Amino Acid Substitution; Drug Resistance, Viral; Genotype; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase; HIV Integrase Inhibitors; HIV-1; Humans; Inhibitory Concentration 50; Mutation; Oxazines; Phenotype; Phylogeny; Piperazines; Polymorphism, Genetic; Pyridones; Quinolones; Raltegravir Potassium | 2017 |
Mutations Located outside the Integrase Gene Can Confer Resistance to HIV-1 Integrase Strand Transfer Inhibitors.
Topics: Amino Acid Substitution; Cell Line; Drug Resistance, Viral; Genes, nef; Heterocyclic Compounds, 3-Ring; High-Throughput Nucleotide Sequencing; HIV Infections; HIV Integrase; HIV Integrase Inhibitors; HIV-1; Humans; Mutation; Oxazines; Piperazines; Pyridones; Quinolones; Raltegravir Potassium; Virus Integration; Virus Replication; Zidovudine | 2017 |
Effect of Cobicistat on Tenofovir Disoproxil Fumarate (TDF): What Is True for TAF May Also Be True for TDF.
Topics: Adenine; Adult; Aged; Alanine; Anti-HIV Agents; Cobicistat; Drug Combinations; Drug Interactions; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Oxazines; Piperazines; Proportional Hazards Models; Pyridones; Quinolones; Raltegravir Potassium; Ritonavir; Tenofovir; Treatment Outcome | 2018 |
Adverse drug reactions to integrase strand transfer inhibitors.
Topics: Adult; British Columbia; Cobicistat; Drug-Related Side Effects and Adverse Reactions; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; Humans; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Quinolones; Raltegravir Potassium; Retrospective Studies | 2018 |
Reciprocal Effects of Antiretroviral Drugs Used To Treat HIV Infection on the Fibroblast Growth Factor 21/β-Klotho System.
Topics: Adipose Tissue; Alkynes; Anti-Retroviral Agents; Benzoxazines; Cyclopropanes; Diabetes Mellitus, Type 2; Drug Combinations; Endoplasmic Reticulum Stress; Fibroblast Growth Factors; Hep G2 Cells; HIV Infections; HIV Integrase Inhibitors; Humans; Klotho Proteins; Liver; Lopinavir; Maraviroc; Membrane Proteins; Muscle, Skeletal; Obesity; Oxidative Stress; Protease Inhibitors; Quinolones; Reverse Transcriptase Inhibitors; Ritonavir; Thapsigargin; Tunicamycin | 2018 |
2018 update to the HIV-TRePS system: the development of new computational models to predict HIV treatment outcomes, with or without a genotype, with enhanced usability for low-income settings.
Topics: Adult; Anti-HIV Agents; Computer Simulation; Developing Countries; Drug Substitution; Female; HIV Infections; Humans; Male; Maraviroc; Pyridines; Pyrones; Quinolones; Sulfonamides; Sustained Virologic Response; Treatment Outcome | 2018 |
Dolutegravir (DTG)-containing regimens after receiving raltegravir (RAL) or elvitegravir (EVG): Durability and virological response in a large Italian HIV drug resistance network (ARCA).
Topics: Adult; Anti-HIV Agents; Cohort Studies; Drug Resistance, Multiple, Viral; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Quinolones; Raltegravir Potassium; Retrospective Studies; RNA, Viral; Sustained Virologic Response; Young Adult | 2018 |
Selective resistance profiles emerging in patient-derived clinical isolates with cabotegravir, bictegravir, dolutegravir, and elvitegravir.
Topics: Amides; Anti-HIV Agents; Drug Resistance, Viral; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV Integrase; HIV Integrase Inhibitors; HIV-1; Humans; Mutation; Oxazines; Piperazines; Pyridones; Quinolones; Virus Replication | 2018 |
Overdose of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in an HIV-1-infected subject with attempted suicide.
Topics: Adenine; Alanine; Anti-HIV Agents; Cobicistat; Drug Combinations; Drug Overdose; Emtricitabine; HIV Infections; Humans; Male; Middle Aged; Quinolones; Renal Insufficiency; Suicide, Attempted; Tenofovir | 2019 |
Optimizing concentrations of concomitant antiretrovirals by reducing etravirine doses: two case reports of complex drug-drug interactions.
Topics: Anti-Retroviral Agents; Darunavir; Drug Interactions; Drug Monitoring; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Male; Middle Aged; Nitriles; Oxazines; Piperazines; Pyridazines; Pyridones; Pyrimidines; Quinolones | 2019 |
Efficacy and safety of switching to dolutegravir plus emtricitabine/tenofovir disoproxil fumarate (TDF) or elvitegravir/cobicistat/emtricitabine/TDF in virologically suppressed HIV-infected patients in clinical practice: results from a multicentre, observ
Topics: Adult; Cobicistat; Drug Therapy, Combination; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Quinolones; Retrospective Studies; RNA, Viral; Tenofovir; Viral Load | 2019 |
Prevalence and determinants of resistance mutations in HIV-1-infected patients exposed to integrase inhibitors in a large Italian cohort.
Topics: Adult; Drug Resistance, Viral; Female; Genotype; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase; HIV Integrase Inhibitors; HIV-1; Humans; Italy; Logistic Models; Male; Middle Aged; Mutation; Oxazines; Piperazines; Prevalence; Pyridones; Quinolones; Raltegravir Potassium | 2019 |
Abnormal elevation of international normalized ratio in a patient during the coadministration of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide and warfarin: a case report.
Topics: Adenine; Alanine; Cobicistat; Emtricitabine; HIV Infections; Humans; International Normalized Ratio; Quinolones; Tenofovir; Warfarin | 2019 |
Brief Report: Surveillance of Congenital Anomalies After Exposure to Raltegravir or Elvitegravir During Pregnancy in the United Kingdom and Ireland, 2008-2018.
Topics: Abnormalities, Drug-Induced; Adult; Female; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Ireland; Pregnancy; Pregnancy Complications, Infectious; Quinolones; Raltegravir Potassium; Stillbirth; United Kingdom | 2019 |
Integrase strand transfer inhibitors and neuropsychiatric adverse events in a large prospective cohort.
Topics: Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cohort Studies; Female; France; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; Humans; Male; Mental Disorders; Nervous System Diseases; Oxazines; Piperazines; Prospective Studies; Public Health Surveillance; Pyridones; Quinolones; Raltegravir Potassium; Viral Load | 2019 |
Barrier to Resistance of Dolutegravir in Two-Drug Combinations.
Topics: Anti-HIV Agents; Cell Line; Drug Resistance, Viral; Drug Therapy, Combination; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; HIV-1; Humans; Lamivudine; Oxazines; Piperazines; Pyridones; Quinolones; Rilpivirine | 2019 |
HIV Integrase Inhibitor Pharmacogenetics: An Exploratory Study.
Topics: Adult; Female; Genotype; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; Humans; Male; Middle Aged; Oxazines; Pharmacogenetics; Piperazines; Pyridones; Quinolones; Raltegravir Potassium | 2019 |
Discontinuation of dolutegravir, elvitegravir/cobicistat and raltegravir because of toxicity in a prospective cohort.
Topics: Adult; CD4 Lymphocyte Count; Cobicistat; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Male; Middle Aged; Oxazines; Piperazines; Proportional Hazards Models; Prospective Studies; Pyridones; Quinolones; Raltegravir Potassium; Spain | 2019 |
Durability of first-line regimens including integrase strand transfer inhibitors (INSTIs): data from a real-life setting.
Topics: Adult; CD4 Lymphocyte Count; Cobicistat; Cohort Studies; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; HIV Seropositivity; Humans; Italy; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Quinolones; Raltegravir Potassium; Regression Analysis; Survival Analysis; Treatment Failure | 2019 |
Severe rhabdomyolysis-induced acute kidney injury following concomitant use of Genvoya® (EVG/COBI/FTC/TAF) and simvastatin; a case report.
Topics: Acute Kidney Injury; Anti-HIV Agents; Cobicistat; Drug Combinations; Drug Interactions; Dyslipidemias; Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Emtricitabine; Hepatitis A; Hepatitis C; HIV Infections; Humans; Hypolipidemic Agents; Liver Function Tests; Male; Middle Aged; Quinolones; Renal Dialysis; Rhabdomyolysis; Simvastatin; Tenofovir; Treatment Outcome | 2019 |
Antiretroviral Hydrophobic Core Graft-Copolymer Nanoparticles: The Effectiveness against Mutant HIV-1 Strains and in Vivo Distribution after Topical Application.
Topics: Alkynes; Animals; Anti-HIV Agents; Benzoxazines; Cell Line; Cyclopropanes; Drug Carriers; Drug Combinations; Drug Liberation; Drug Resistance, Viral; Female; HIV Infections; HIV Integrase Inhibitors; HIV-1; Hydrophobic and Hydrophilic Interactions; Molecular Dynamics Simulation; Mutation; Nanoparticles; Polyethylene Glycols; Polylysine; Quinolones; Rats; Reverse Transcriptase Inhibitors; Tissue Distribution | 2019 |
Paediatric Integrase Inhibitor Use in a Real-Life Setting: A Single-Centre Cohort Experience 2009-2018.
Topics: Adolescent; Child; Child, Preschool; Cohort Studies; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; Humans; Male; Oxazines; Piperazines; Pyridones; Quinolones; Raltegravir Potassium; Retrospective Studies; Viral Load | 2019 |
Effects of guggulsterones-containing thermogenic complex on elvitegravir plasma concentrations: a case report.
Topics: Anti-HIV Agents; CD4-Positive T-Lymphocytes; Cytochrome P-450 CYP3A; Drug Interactions; HIV Infections; Humans; Lymphocyte Count; Male; Middle Aged; Pregnenediones; Quinolones; RNA, Viral | 2019 |
Is There a Safety Signal for Dolutegravir and Integrase Inhibitors During Pregnancy?
Topics: Adult; Anti-Retroviral Agents; Cohort Studies; Congenital Abnormalities; Drug Resistance, Viral; Female; France; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; HIV-1; Humans; Neural Tube Defects; Oxazines; Pharmacovigilance; Piperazines; Pregnancy; Pyridones; Quinolones; Raltegravir Potassium; Treatment Outcome; Young Adult | 2019 |
Resistance to HIV integrase strand transfer inhibitors in Argentina: first interim survey.
Topics: Adult; Argentina; Drug Resistance, Viral; Female; Heterocyclic Compounds, 3-Ring; HIV; HIV Infections; HIV Integrase Inhibitors; Humans; Male; Middle Aged; Oxazines; Pilot Projects; Piperazines; Prevalence; Pyridones; Quinolones; Raltegravir Potassium; Retrospective Studies; Surveys and Questionnaires; Urban Population; Viral Load; Young Adult | 2019 |
E157Q integrase strand-transfer inhibitor substitution in patients with acute/recent HIV infection.
Topics: Adult; Amino Acid Substitution; Disease Transmission, Infectious; Drug Resistance, Viral; Female; Gene Frequency; Genotype; Genotyping Techniques; High-Throughput Nucleotide Sequencing; HIV; HIV Infections; HIV Integrase; HIV Integrase Inhibitors; Humans; Male; Molecular Epidemiology; Mutation, Missense; Phylogeny; Prevalence; Prospective Studies; Quinolones; Raltegravir Potassium; Sexual and Gender Minorities; Viral Load | 2019 |
Sustained HIV virologic suppression with crushed combination tablets containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide.
Topics: Adenine; Alanine; Anti-HIV Agents; Cobicistat; Drug Therapy, Combination; Emtricitabine; Enteral Nutrition; Gastrostomy; HIV Infections; HIV-1; Humans; Male; Middle Aged; Quinolones; Sustained Virologic Response; Tablets; Tenofovir | 2019 |
Evaluation of HIV-1 integrase resistance emergence and evolution in patients treated with integrase inhibitors.
Topics: Adult; Drug Resistance, Viral; Evolution, Molecular; Female; Genotype; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase; HIV Integrase Inhibitors; HIV-1; Humans; Logistic Models; Male; Middle Aged; Mutation; Oxazines; Piperazines; Pyridones; Quinolones; Raltegravir Potassium | 2020 |
Brief Report: Urine Emtricitabine and Tenofovir Concentrations Provide Markers of Recent Antiretroviral Drug Exposure Among HIV-Negative Men Who Have Sex With Men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Alanine; Anti-HIV Agents; Anti-Retroviral Agents; Biomarkers; Cobicistat; Emtricitabine; HIV Infections; Homosexuality, Male; Humans; Male; Middle Aged; Quinolones; Sexual and Gender Minorities; Tenofovir; Time Factors; Young Adult | 2019 |
Antiviral activity of HIV-1 integrase strand-transfer inhibitors against mutants with integrase resistance-associated mutations and their frequency in treatment-naïve individuals.
Topics: Amides; Drug Resistance, Viral; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV Integrase; HIV Integrase Inhibitors; HIV-1; Humans; Mutation; Oxazines; Piperazines; Polymorphism, Genetic; Pyridones; Quinolones | 2019 |
Impact of primary elvitegravir resistance-associated mutations in HIV-1 integrase on drug susceptibility and viral replication fitness.
Topics: Cell Line; Drug Resistance, Viral; Genotype; HEK293 Cells; HIV Infections; HIV Integrase; HIV-1; Humans; Microbial Sensitivity Tests; Mutation; Quinolones; Virus Replication | 2013 |
The pharmacokinetic and pharmacodynamic interactions between buprenorphine/naloxone and elvitegravir/cobicistat in subjects receiving chronic buprenorphine/naloxone treatment.
Topics: Adult; Anti-Retroviral Agents; Area Under Curve; Buprenorphine; Carbamates; Cobicistat; Drug Interactions; Female; HIV Infections; HIV Seronegativity; Humans; Male; Middle Aged; Naloxone; Narcotic Antagonists; Opioid-Related Disorders; Quinolones; Thiazoles | 2013 |
A validated assay by liquid chromatography-tandem mass spectrometry for the simultaneous quantification of elvitegravir and rilpivirine in HIV positive patients.
Topics: Anti-Retroviral Agents; Chromatography, Liquid; Drug Stability; HIV Infections; Humans; Nitriles; Pyrimidines; Quinolones; Reproducibility of Results; Rilpivirine; Sensitivity and Specificity; Tandem Mass Spectrometry | 2013 |
Multiple genetic pathways involving amino acid position 143 of HIV-1 integrase are preferentially associated with specific secondary amino acid substitutions and confer resistance to raltegravir and cross-resistance to elvitegravir.
Topics: Amino Acid Substitution; Drug Resistance, Viral; Genes, Reporter; HEK293 Cells; HIV Infections; HIV Integrase; HIV Integrase Inhibitors; HIV-1; Humans; Luciferases; Mutagenesis, Site-Directed; Pyrrolidinones; Quinolones; Raltegravir Potassium; Tyrosine | 2013 |
In vitro phenotypes to elvitegravir and dolutegravir in primary macrophages and lymphocytes of clonal recombinant viral variants selected in patients failing raltegravir.
Topics: Anti-HIV Agents; Cells, Cultured; Cloning, Molecular; Drug Resistance, Viral; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase; HIV-1; Humans; Lymphocytes; Macrophages; Oxazines; Piperazines; Pyridones; Pyrrolidinones; Quinolones; Raltegravir Potassium; Recombination, Genetic; Reverse Transcriptase Polymerase Chain Reaction; RNA, Viral; Sequence Analysis, DNA | 2013 |
[ First integrase inhibitor based single tablet regimen].
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Carbamates; Cobicistat; Deoxycytidine; Drug Approval; Drug Combinations; Emtricitabine; HIV Infections; HIV Integrase Inhibitors; Humans; Organophosphonates; Quinolones; Tenofovir; Thiazoles; Treatment Outcome | 2013 |
Discovery of a small molecule agonist of phosphatidylinositol 3-kinase p110α that reactivates latent HIV-1.
Topics: Anti-HIV Agents; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Line; Class Ia Phosphatidylinositol 3-Kinase; Drug Discovery; Drug Therapy, Combination; Enzyme Activation; Gene Expression; Heterocyclic Compounds, 4 or More Rings; Histone Deacetylase Inhibitors; HIV Infections; HIV-1; Humans; Hydroxamic Acids; Lymphocyte Activation; Lymphocyte Depletion; Proto-Oncogene Proteins c-akt; Quinolones; Signal Transduction; Virus Activation; Virus Latency; Vorinostat | 2014 |
Examining structural analogs of elvitegravir as potential inhibitors of HIV-1 integrase.
Topics: Amino Acid Motifs; Amino Acid Sequence; Drug Resistance, Viral; HIV Infections; HIV Integrase; HIV Integrase Inhibitors; HIV-1; Humans; Molecular Docking Simulation; Molecular Structure; Quinolones | 2014 |
Single-tablet, once-daily treatment regimens for HIV.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; Cobicistat; Cyclopropanes; Cytochrome P-450 CYP3A Inhibitors; Deoxycytidine; Drug Combinations; Emtricitabine; HIV Infections; HIV Integrase Inhibitors; HIV Reverse Transcriptase; Humans; Nitriles; Organophosphonates; Pyrimidines; Quinolones; Reverse Transcriptase Inhibitors; Rilpivirine; Tenofovir; Thiazoles | 2014 |
Elvitegravir for the treatment of HIV infection.
Topics: Animals; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Administration Schedule; Drug Interactions; Drug Resistance, Viral; Drug Therapy, Combination; Half-Life; HIV Infections; HIV Integrase Inhibitors; Humans; Quinolones; Ritonavir | 2014 |
New raltegravir resistance pathways induce broad cross-resistance to all currently used integrase inhibitors.
Topics: Amino Acid Substitution; Drug Resistance, Viral; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase; HIV Integrase Inhibitors; HIV-1; Humans; Mutation; Oxazines; Piperazines; Protein Binding; Pyridones; Pyrrolidinones; Quinolones; Raltegravir Potassium; Treatment Failure | 2014 |
Sustained virological response after taking crushed elvitegravir-cobicistat-emtricitabine-tenofovir tablets.
Topics: Adenine; Adult; Antiretroviral Therapy, Highly Active; Carbamates; Cobicistat; Deoxycytidine; Emtricitabine; Female; HIV; HIV Infections; Humans; Organophosphonates; Powders; Quinolones; Tablets; Tenofovir; Thiazoles; Viral Load | 2014 |
Lack of resistance to integrase inhibitors among antiretroviral-naive subjects with primary HIV-1 infection, 2007-2013.
Topics: Adult; Drug Resistance, Viral; Genotype; HIV Infections; HIV Integrase; HIV Integrase Inhibitors; HIV-1; Humans; Male; Mutation; Quinolones; Raltegravir Potassium; Retrospective Studies; Sequence Analysis, RNA | 2015 |
Switching STRATEGIES in HIV treatment.
Topics: Adenine; Anti-HIV Agents; Carbamates; Cobicistat; Deoxycytidine; Emtricitabine; Female; HIV; HIV Infections; Humans; Male; Organophosphonates; Protease Inhibitors; Quinolones; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Thiazoles | 2014 |
Virological and immunological outcomes of elvitegravir-based regimen in a treatment-naïve HIV-2-infected patient.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; HIV Infections; HIV-2; Humans; Male; Middle Aged; Quinolones; Time Factors; Treatment Outcome; Viral Load | 2014 |
Suppression of Foxo1 activity and down-modulation of CD62L (L-selectin) in HIV-1 infected resting CD4 T cells.
Topics: CD4-Positive T-Lymphocytes; Forkhead Box Protein O1; Forkhead Transcription Factors; Gene Expression Regulation; HIV Infections; HIV-1; Humans; Kruppel-Like Transcription Factors; L-Selectin; Lymphocyte Activation; Lymphoid Tissue; Quinolones; Receptors, Interleukin-7; Virus Replication | 2014 |
Antiviral characteristics of GSK1265744, an HIV integrase inhibitor dosed orally or by long-acting injection.
Topics: Anti-HIV Agents; Cell Line; Drug Resistance, Viral; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase; HIV Integrase Inhibitors; HIV-1; Humans; Microbial Sensitivity Tests; Oxazines; Piperazines; Pyridones; Quinolones; Raltegravir Potassium; Virus Replication | 2015 |
Elvitegravir/cobicistat/emtricitabine/tenofovir DF in HIV-infected patients with mild-to-moderate renal impairment.
Topics: Adenine; Adult; Anti-HIV Agents; Carbamates; Cobicistat; Cohort Studies; Deoxycytidine; Emtricitabine; Female; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Quinolones; Renal Insufficiency; Tenofovir; Thiazoles; Treatment Outcome | 2015 |
Cross-resistance to elvitegravir and dolutegravir in 502 patients failing on raltegravir: a French national study of raltegravir-experienced HIV-1-infected patients.
Topics: Adult; Anti-HIV Agents; Drug Resistance, Viral; Female; France; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase; HIV Protease; HIV Reverse Transcriptase; HIV-1; Humans; Male; Middle Aged; Mutant Proteins; Oxazines; Piperazines; Pyridones; Quinolones; Raltegravir Potassium; Sequence Analysis, DNA | 2015 |
Tenofovir alafenamide for HIV infection: is less more?
Topics: Adenine; Alanine; Anti-HIV Agents; Carbamates; Cobicistat; Deoxycytidine; Emtricitabine; Female; HIV Infections; Humans; Male; Organophosphonates; Quinolones; Tenofovir; Thiazoles | 2015 |
An unexpected interaction between warfarin and cobicistat-boosted elvitegravir.
Topics: Adult; Anti-HIV Agents; Cobicistat; Drug Interactions; HIV Infections; Humans; Male; Quinolones; Warfarin | 2015 |
Infectious disease: New HIV-1 prodrug shows promise in phase III trials.
Topics: Adenine; Anti-HIV Agents; Carbamates; Deoxycytidine; Female; HIV Infections; Humans; Male; Organophosphonates; Quinolones; Thiazoles | 2015 |
Rapid regression of Kaposi's sarcoma of the hard palate under therapy with boosted elvitegravir-containing fixdose antiretroviral combination therapy.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; HIV Infections; Humans; Male; Palatal Neoplasms; Palate, Hard; Quinolones; Sarcoma, Kaposi; Treatment Outcome | 2016 |
N-Substituted Quinolinonyl Diketo Acid Derivatives as HIV Integrase Strand Transfer Inhibitors and Their Activity against RNase H Function of Reverse Transcriptase.
Topics: Catalytic Domain; HeLa Cells; HIV Infections; HIV Integrase; HIV Integrase Inhibitors; HIV-1; Humans; Keto Acids; Models, Molecular; Molecular Structure; Quinolones; Ribonuclease H; RNA-Directed DNA Polymerase; Structure-Activity Relationship; Virus Replication | 2015 |
The Combination of the R263K and T66I Resistance Substitutions in HIV-1 Integrase Is Incompatible with High-Level Viral Replication and the Development of High-Level Drug Resistance.
Topics: Amino Acid Substitution; Cell Line, Tumor; Drug Resistance, Viral; HEK293 Cells; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase; HIV Integrase Inhibitors; HIV-1; Humans; Oxazines; Piperazines; Pyridones; Quinolones; Raltegravir Potassium; Virus Replication | 2015 |
Deep analysis of HIV-1 natural variability across HIV-1 variants at residues associated with integrase inhibitor (INI) resistance in INI-naive individuals.
Topics: Amino Acid Substitution; Computational Biology; Drug Resistance, Viral; Genetic Variation; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase; HIV Integrase Inhibitors; HIV-1; Humans; Oxazines; Piperazines; Pyridones; Quinolones; Raltegravir Potassium | 2016 |
Elvitegravir (Vitekta) for HIV.
Topics: Animals; Drug Interactions; Female; HIV Infections; HIV Integrase; HIV Integrase Inhibitors; HIV-1; Humans; Pregnancy; Quinolones; Risk Factors; Treatment Outcome | 2016 |
Genvoya--a new 4-drug combination for HIV.
Topics: Cobicistat; Drug Combinations; Drug Interactions; Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Emtricitabine; HIV Infections; HIV Integrase Inhibitors; HIV-1; Humans; Quinolones; Randomized Controlled Trials as Topic; Tenofovir; Treatment Outcome | 2016 |
First reported use of elvitegravir and cobicistat during pregnancy.
Topics: Adult; Anti-HIV Agents; Cobicistat; Female; HIV Infections; Humans; Plasma; Pregnancy; Pregnancy Complications, Infectious; Quinolones | 2016 |
Elvitegravir/Cobicistat/Tenofovir/Emtricitabine Penetration in the Cerebrospinal Fluid of Three HIV-Positive Patients.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cobicistat; Emtricitabine; Female; HIV Infections; Humans; Male; Middle Aged; Quinolones; Tenofovir | 2016 |
Q148N, a Novel Integrase Inhibitor Resistance Mutation Associated with Low-Level Reduction in Elvitegravir Susceptibility.
Topics: Amino Acid Substitution; Drug Resistance, Viral; HIV Infections; HIV Integrase; HIV Integrase Inhibitors; HIV-1; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Mutation, Missense; Quinolones | 2016 |
HIV-infected CD4+ T Cells Use T-bet-dependent Pathway for Production of IL-10 Upon Antigen Recognition.
Topics: Adult; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Cells, Cultured; Cyclosporine; Extracellular Signal-Regulated MAP Kinases; Female; Flavonoids; Forkhead Transcription Factors; HIV Core Protein p24; HIV Infections; Humans; Interferon-gamma; Interleukin-10; Lymphocyte Activation; Male; Middle Aged; Quinolones; T-Box Domain Proteins; Young Adult | 2016 |
Population pharmacokinetic analysis of elvitegravir and cobicistat in HIV-1-infected individuals.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Area Under Curve; Cobicistat; Cohort Studies; Computer Simulation; Drug Interactions; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Models, Statistical; Quinolones; Young Adult | 2016 |
The development and application of a novel LC-MS/MS method for the measurement of Dolutegravir, Elvitegravir and Cobicistat in human plasma.
Topics: Anti-HIV Agents; Chromatography, High Pressure Liquid; Cobicistat; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; Humans; Limit of Detection; Liquid-Liquid Extraction; Oxazines; Piperazines; Pyridones; Quinolones; Tandem Mass Spectrometry | 2016 |
Elvitegravir/cobicistat-associated toxic optical neuropathy in an HIV-infected patient: a call for caution?
Topics: Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cobicistat; HIV Infections; HIV-1; Humans; Male; Middle Aged; Optic Nerve Diseases; Quinolones; Viral Load | 2017 |
Simultaneous quantification of tenofovir, emtricitabine, rilpivirine, elvitegravir and dolutegravir in mouse biological matrices by LC-MS/MS and its application to a pharmacokinetic study.
Topics: Animals; Anti-Retroviral Agents; Chromatography, Liquid; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Mice; Oxazines; Piperazines; Pyridones; Quinolones; Rilpivirine; Solid Phase Extraction; Tandem Mass Spectrometry; Tenofovir | 2016 |
Development of a phenotypic susceptibility assay for HIV-1 integrase inhibitors.
Topics: Drug Resistance, Viral; Genotype; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase; HIV Integrase Inhibitors; HIV-1; Humans; Mutation; Oxazines; Phenotype; Piperazines; Pyridones; Quinolones; Raltegravir Potassium | 2016 |
Efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate as treatment for primary or recent HIV infection.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cobicistat; Emtricitabine; HIV; HIV Infections; Humans; Male; Middle Aged; Quinolones; Retrospective Studies; Tenofovir; Treatment Outcome; Viral Load | 2017 |
Pharmacokinetic interactions between cobicistat-boosted elvitegravir and darunavir in HIV-infected patients.
Topics: Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Cobicistat; Darunavir; Drug Combinations; Drug Interactions; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Quinolones; Young Adult | 2017 |
Unravelling the dynamics of selection of multiresistant variants to integrase inhibitors in an HIV-1-infected child using ultra-deep sequencing.
Topics: Child; Drug Resistance, Viral; Heterocyclic Compounds, 3-Ring; High-Throughput Nucleotide Sequencing; HIV Infections; HIV Integrase; HIV Integrase Inhibitors; HIV-1; Humans; Mutation; Oxazines; Piperazines; Pyridones; Pyrrolidinones; Quinolones; Raltegravir Potassium; RNA, Viral; Selection, Genetic | 2017 |
Tenofovir alafenamide, emtricitabine, elvitegravir, and cobicistat combination therapy for the treatment of HIV.
Topics: Anti-HIV Agents; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cobicistat; Drug Combinations; Drug Interactions; Emtricitabine; HIV Infections; Humans; Quinolones; Tenofovir | 2017 |
Tenofovir alafenamide and elvitegravir loaded nanoparticles for long-acting prevention of HIV-1 vaginal transmission.
Topics: Adenine; Alanine; Animals; Delayed-Action Preparations; Disease Transmission, Infectious; Female; HIV Infections; Injections, Subcutaneous; Mice; Mice, SCID; Nanoparticles; Plasma; Quinolones; Tenofovir; Treatment Outcome; Vagina; Viral Load | 2017 |
Comment on: Efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate as treatment for primary or recent HIV infection.
Topics: Adenine; Anti-HIV Agents; Cobicistat; Deoxycytidine; Emtricitabine; HIV Infections; Humans; Organophosphonates; Quinolones; Tenofovir | 2017 |
Alterations in cellular pharmacokinetics and pharmacodynamics of elvitegravir in response to ethanol exposure in HIV-1 infected monocytic (U1) cells.
Topics: Anti-HIV Agents; Cell Line; Drug Interactions; Ethanol; HIV Infections; HIV-1; Humans; Monocytes; Quinolones | 2017 |
Structure-activity relationship study on anti-HIV 6-desfluoroquinolones.
Topics: Anti-HIV Agents; Cells, Cultured; HIV Infections; HIV-1; Humans; Quinolines; Quinolones; Structure-Activity Relationship | 2008 |
HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitro.
Topics: Amino Acid Sequence; Amino Acid Substitution; Catalytic Domain; Codon, Nonsense; Cohort Studies; Conserved Sequence; Drug Resistance, Viral; France; HIV Infections; HIV Integrase; HIV-1; HIV-2; Humans; Inhibitory Concentration 50; Integrase Inhibitors; Microbial Sensitivity Tests; Molecular Sequence Data; Mutation, Missense; Polymorphism, Genetic; Pyrrolidinones; Quinolones; Raltegravir Potassium | 2008 |
Clade-specific HIV-1 integrase polymorphisms do not reduce raltegravir and elvitegravir phenotypic susceptibility.
Topics: Drug Resistance, Viral; HIV Infections; HIV Integrase; HIV Integrase Inhibitors; HIV-1; Humans; Polymorphism, Genetic; Pyrrolidinones; Quinolones; Raltegravir Potassium | 2008 |
Elvitegravir, an oral HIV integrase inhibitor, for the potential treatment of HIV infection.
Topics: Biological Availability; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Administration Routes; Drug Administration Schedule; Drug Combinations; Drug Evaluation, Preclinical; HIV Infections; HIV Integrase Inhibitors; HIV-1; Humans; Molecular Structure; Quinolones; Ritonavir | 2009 |
Genetic barriers for integrase inhibitor drug resistance in HIV type-1 B and CRF02_AG subtypes.
Topics: DNA, Viral; Drug Resistance, Viral; Genetic Variation; HIV Infections; HIV Integrase; HIV Integrase Inhibitors; HIV-1; Humans; Mutation; Pyrrolidinones; Quinolones; Raltegravir Potassium; Sequence Analysis, DNA | 2009 |
Treatment of delusional parasitosis with aripiprazole.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Delusions; Female; HIV Infections; Humans; Lupus Erythematosus, Systemic; Male; Middle Aged; Piperazines; Quinolones; Skin Diseases, Parasitic | 2009 |
A combined genotypic and phenotypic human immunodeficiency virus type 1 recombinant virus assay for the reverse transcriptase and integrase genes.
Topics: Drug Resistance, Multiple, Viral; HIV Infections; HIV Integrase; HIV Integrase Inhibitors; HIV Reverse Transcriptase; HIV-1; Humans; Microbial Sensitivity Tests; Polymorphism, Genetic; Pyrrolidinones; Quinolones; Raltegravir Potassium; Reproducibility of Results; Ribonuclease H, Human Immunodeficiency Virus; RNA, Viral; Sensitivity and Specificity; Sequence Analysis, DNA | 2009 |
Synthesis, antiviral activity and molecular modeling of oxoquinoline derivatives.
Topics: Animals; Anti-HIV Agents; Cell Survival; Chlorocebus aethiops; HIV Infections; HIV-1; Humans; Leukocytes, Mononuclear; Models, Molecular; Molecular Structure; Quinolones; Structure-Activity Relationship; Vero Cells | 2009 |
[New antiretroviral drug classes in HIV therapy].
Topics: Anti-HIV Agents; CCR5 Receptor Antagonists; Cyclohexanes; HIV Fusion Inhibitors; HIV Infections; HIV Integrase Inhibitors; HIV-1; Humans; Maraviroc; Piperazines; Pyrimidines; Pyrrolidinones; Quinolones; Raltegravir Potassium; Succinates; Triazoles; Triterpenes; Viral Load | 2009 |
Single-tablet Quad regimen achieves high rate of virologic suppression.
Topics: Adenine; Anti-HIV Agents; Atazanavir Sulfate; CD4 Lymphocyte Count; Clinical Trials, Phase II as Topic; Cytochrome P-450 CYP3A Inhibitors; Deoxycytidine; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; HIV Infections; HIV-1; Humans; Multicenter Studies as Topic; Oligopeptides; Organophosphonates; Organophosphorus Compounds; Oxazines; Pyridines; Quinolones; Randomized Controlled Trials as Topic; Ritonavir; Treatment Outcome; Viral Load | 2010 |
Natural polymorphisms of integrase among HIV type 1-infected South African patients.
Topics: Amino Acid Sequence; Drug Resistance, Multiple, Viral; Genetic Variation; HIV Infections; HIV Integrase; HIV Integrase Inhibitors; HIV-1; Humans; Molecular Sequence Data; Phylogeny; Polymorphism, Single Nucleotide; Pyrrolidinones; Quinolones; Raltegravir Potassium; RNA, Viral; South Africa | 2010 |
HIV-1 resistance patterns to integrase inhibitors in antiretroviral-experienced patients with virological failure on raltegravir-containing regimens.
Topics: Amino Acid Substitution; Drug Resistance, Viral; Genotype; HIV Infections; HIV Integrase; HIV Integrase Inhibitors; HIV-1; Humans; Microbial Sensitivity Tests; Mutation, Missense; Prospective Studies; Pyrrolidinones; Quinolones; Raltegravir Potassium; RNA, Viral; Sequence Analysis, DNA; Treatment Failure; Viral Load | 2010 |
Studies of anti-HIV transcription inhibitor quinolones: identification of potent N1-vinyl derivatives.
Topics: Anti-HIV Agents; Cell Line; HIV Infections; Humans; Quinolones; Structure-Activity Relationship; Transcription, Genetic; Vinyl Compounds; Virus Replication | 2010 |
Increased aripiprazole concentrations in an HIV-positive male concurrently taking duloxetine, darunavir, and ritonavir.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Anxiety; Aripiprazole; Cytochrome P-450 Enzyme Inhibitors; Darunavir; Depression; Dose-Response Relationship, Drug; Duloxetine Hydrochloride; HIV Infections; HIV Protease Inhibitors; Humans; Male; Piperazines; Quinolones; Ritonavir; Sulfonamides; Thiophenes | 2010 |
Structural modifications of quinolone-3-carboxylic acids with anti-HIV activity.
Topics: Anti-HIV Agents; Carboxylic Acids; Cell Line, Tumor; Cell Survival; HIV Infections; HIV Seropositivity; HIV-1; Humans; Models, Molecular; Quinolones; Structure-Activity Relationship | 2011 |
Microwave assisted organic synthesis (MAOS) of small molecules as potential HIV-1 integrase inhibitors.
Topics: Green Chemistry Technology; HIV Infections; HIV Integrase; HIV Integrase Inhibitors; HIV-1; Humans; Indoles; Kinetics; Magnetic Resonance Spectroscopy; Microwaves; Models, Molecular; Molecular Structure; Pyrrolidinones; Quinolones; Raltegravir Potassium; Small Molecule Libraries; Structure-Activity Relationship | 2011 |
Elvitegravir: a once daily alternative to raltegravir.
Topics: Anti-Retroviral Agents; Female; HIV Infections; HIV-1; Humans; Male; Pyrrolidinones; Quinolones; Raltegravir Potassium | 2012 |
Molecular dynamics approaches estimate the binding energy of HIV-1 integrase inhibitors and correlate with in vitro activity.
Topics: Amino Acid Substitution; Binding Sites; DNA, Viral; Drug Design; Drug Resistance, Viral; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase; HIV Integrase Inhibitors; HIV-1; Humans; Molecular Dynamics Simulation; Mutation; Oxazines; Piperazines; Protein Binding; Pyridones; Pyrrolidinones; Quantitative Structure-Activity Relationship; Quinolones; Raltegravir Potassium; Spumavirus; Thermodynamics | 2012 |
In vitro resistance selections using elvitegravir, raltegravir, and two metabolites of elvitegravir M1 and M4.
Topics: Cell Line; Drug Resistance, Viral; HIV Infections; HIV Integrase; HIV Integrase Inhibitors; HIV-1; Humans; Mutation; Pyrrolidinones; Quinolones; Raltegravir Potassium | 2012 |
Broad phenotypic cross-resistance to elvitegravir in HIV-infected patients failing on raltegravir-containing regimens.
Topics: Drug Resistance, Viral; Genotype; HIV Infections; HIV Integrase Inhibitors; Humans; Molecular Sequence Data; Pyrrolidinones; Quinolones; Raltegravir Potassium | 2012 |
Genetic barrier to the development of resistance to integrase inhibitors in HIV-1 subtypes CRF01_AE and B.
Topics: Amino Acid Substitution; Drug Resistance, Viral; Genotype; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase; HIV Integrase Inhibitors; HIV-1; Humans; Mutant Proteins; Mutation, Missense; Oxazines; Piperazines; Pyridones; Pyrrolidinones; Quinolones; Raltegravir Potassium; RNA, Viral; Sequence Analysis, DNA | 2012 |
The elvitegravir Quad pill: the first once-daily dual-target anti-HIV tablet.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Carbamates; Clinical Trials as Topic; Deoxycytidine; Drug Administration Schedule; Drug Combinations; Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; HIV Infections; Humans; Organophosphonates; Quinolones; Tablets; Thiazoles | 2012 |
[A single tablet against HIV: new combination preparation improves therapy].
Topics: Adenine; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; Carbamates; CD4 Lymphocyte Count; Clinical Trials, Phase III as Topic; Cobicistat; Cyclopropanes; Deoxycytidine; Double-Blind Method; Drug Combinations; Drug Resistance, Viral; Emtricitabine; Glomerular Filtration Rate; HIV Infections; Humans; Oligopeptides; Organophosphonates; Pyridines; Quinolones; Randomized Controlled Trials as Topic; Ritonavir; Tenofovir; Thiazoles; Viral Load | 2012 |
FDA approves new 4-drug once-a-day HIV treatment.
Topics: Adenine; Carbamates; Cobicistat; Deoxycytidine; Drug Administration Schedule; Drug Approval; Drug Combinations; Emtricitabine; HIV Infections; Humans; Organophosphonates; Quinolones; Tenofovir; Thiazoles; United States; United States Food and Drug Administration | 2012 |
A 4-drug combination (Stribild) for HIV.
Topics: Adenine; Anti-HIV Agents; Carbamates; Clinical Trials as Topic; Cobicistat; Deoxycytidine; Double-Blind Method; Drug Approval; Drug Combinations; Drug Interactions; Drug Resistance, Multiple, Viral; Emtricitabine; HIV; HIV Infections; Humans; Organophosphonates; Quinolones; Randomized Controlled Trials as Topic; Tenofovir; Thiazoles; United States; United States Food and Drug Administration | 2012 |
Elvitegravir/cobicistat, mirabegron, and linaclotide.
Topics: Acetanilides; Adenine; Anti-Retroviral Agents; Carbamates; Constipation; Deoxycytidine; Drug Combinations; Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; HIV Infections; HIV-1; Humans; Organophosphonates; Peptides; Quinolones; Thiazoles; Urinary Bladder, Overactive | 2012 |
Novel HIV-1 treatment Stribild™ gains regulatory approval.
Topics: Adenine; Anti-HIV Agents; Carbamates; Deoxycytidine; Drug Approval; Drug Combinations; Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; HIV; HIV Infections; Humans; Organophosphonates; Quinolones; Thiazoles | 2012 |
Improved adherence expected with new HIV combo treatment.
Topics: Adenine; Aged; Aged, 80 and over; Anti-HIV Agents; Carbamates; Deoxycytidine; Drug Combinations; Drug Labeling; Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; HIV Infections; Humans; Medication Adherence; Middle Aged; Organophosphonates; Quinolones; Randomized Controlled Trials as Topic; Thiazoles; United States | 2012 |
Multiple choices for HIV therapy with integrase strand transfer inhibitors.
Topics: Clinical Trials as Topic; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase; HIV Integrase Inhibitors; HIV-1; Humans; Oxazines; Piperazines; Pyridones; Pyrrolidinones; Quinolones; Raltegravir Potassium | 2012 |
A review of rilpivirine and elvitegravir resistance features and implications for treatment sequencing.
Topics: Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; HIV Infections; HIV Integrase Inhibitors; Humans; Nitriles; Pyrimidines; Quinolones; Reverse Transcriptase Inhibitors; Rilpivirine | 2012 |
Characterization of pathogenic Escherichia coli in human immunodeficiency virus-related diarrhea in Senegal.
Topics: Anti-Bacterial Agents; Bacterial Adhesion; Case-Control Studies; Child; Diarrhea; Drug Resistance, Multiple, Bacterial; Escherichia coli; Escherichia coli Infections; Feces; Genes, Bacterial; HIV Infections; HIV-1; HIV-2; Humans; Microbial Sensitivity Tests; Prevalence; Quinolones; Risk Factors; Senegal; Virulence; Virulence Factors | 2004 |
Mitochondrial toxicity associated with HAART following liver transplantation in an HIV-infected recipient.
Topics: Acidosis, Lactic; Adult; Antiretroviral Therapy, Highly Active; Azepines; Biopsy, Needle; Comorbidity; Fluoroquinolones; Hepatitis C; HIV Infections; Humans; Liver; Liver Transplantation; Male; Mitochondria, Liver; Necrosis; Postoperative Period; Quinolones | 2004 |
Novel in vivo model for the study of human immunodeficiency virus type 1 transcription inhibitors: evaluation of new 6-desfluoroquinolone derivatives.
Topics: Animals; Anti-HIV Agents; Cell Line; Disease Models, Animal; HIV Infections; HIV-1; Humans; Mice; Mice, SCID; Models, Biological; Quinolones | 2007 |
New results for integrase inhibitor.
Topics: Drug Administration Schedule; HIV Infections; HIV Integrase Inhibitors; Humans; Quinolones; Randomized Controlled Trials as Topic | 2007 |
Resistance to integrase inhibitors.
Topics: Drug Resistance, Viral; HIV Infections; HIV Integrase Inhibitors; Humans; Quinolones | 2007 |
Prior antimicrobials and staphylococcal bacteremia in HIV-infected patients.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Bacterial Agents; Bacteremia; Case-Control Studies; Cohort Studies; Drug Resistance, Microbial; Female; HIV Infections; Humans; Macrolides; Male; Multivariate Analysis; Pentamidine; Quinolones; Rifabutin; Risk Factors; Staphylococcal Infections; Sulfamethoxazole; Trimethoprim | 1997 |
QSAR study and VolSurf characterization of anti-HIV quinolone library.
Topics: Anti-HIV Agents; Computer-Aided Design; Databases, Factual; Drug Design; HIV; HIV Infections; Humans; Models, Chemical; Multivariate Analysis; Quantitative Structure-Activity Relationship; Quinolones; Software | 2001 |
Campylobacter laridis colitis in a human immunodeficiency virus-positive patient treated with a quinolone.
Topics: Adult; Campylobacter Infections; Colitis; Female; HIV Infections; Humans; Quinolones | 1992 |
[Acute Campylobacter jejuni enterocolitis resistant to quinolones in an HIV-positive patient].
Topics: Adult; Campylobacter Infections; Campylobacter jejuni; Drug Resistance, Microbial; Enterocolitis; HIV Infections; Humans; Male; Quinolones | 1992 |
[In vitro activity of twenty antibiotics against Rhodococcus equi].
Topics: Actinomycetales Infections; Aminoglycosides; Anti-Bacterial Agents; Dose-Response Relationship, Drug; Doxycycline; Drug Resistance, Microbial; HIV Infections; Humans; In Vitro Techniques; Lactams; Macrolides; Opportunistic Infections; Quinolones; Rhodococcus; Rifampin | 1991 |